Bio-AMD Inc. - FORM 10-K - March 30, 2016

Attached files

file	filename
EX-32.1 - EX-32.1 - Bio-AMD Inc.	ex32-1.htm
EX-31.2 - EX-31.2 - Bio-AMD Inc.	ex31-2.htm
EX-32.2 - EX-32.2 - Bio-AMD Inc.	ex32-2.htm
EX-21 - EX-21 - Bio-AMD Inc.	ex21.htm
EX-31.1 - EX-31.1 - Bio-AMD Inc.	ex31-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

(Mark One)

x	ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For Fiscal Year Ended: December 31, 2015

o	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

Commission file number: 000-52601

BIO-AMD, INC.

(Exact name of registrant as specified in its charter)

Nevada		20-5242826
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

Daresbury Innovation Centre, Keckwick Lane, Daresbury, UK		WA4 4FS
(Address of principal executive offices)		(Postal Code)

Issuer's telephone number: +44 (0) 8445 861910

Securities registered under Section 12(b) of the Act: None

Securities registered under Section 12(g) of the Act: Common Stock, par value $0.001 par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes o No x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of the “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer o	Accelerated Filer o
Non-Accelerated Filer o	Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of June 30, 2015, there were 45,975,966 shares of the registrant's common stock, par value $0.001, issued and outstanding. Of these, 44,923,584 shares were held by non-affiliates of the registrant. The market value of securities held by non-affiliates was approximately $5,840,066 based on the closing price of $0.13 for the registrant’s common stock on June 30, 2015.

As of March 21, 2016 there were 45,975,966 shares of the registrant’s common stock, $0.001 par value per share, issued and outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Not Applicable.

Table of Contents

TABLE OF CONTENTS

Item Number and Caption		Page

FORWARD-LOOKING STATEMENTS		3

PART I		4
ITEM 1.	BUSINESS	4
ITEM 1A.	RISK FACTORS	14
ITEM 1B.	UNRESOLVED STAFF COMMENTS	22
ITEM 2.	PROPERTIES	22
ITEM 3.	LEGAL PROCEEDINGS	22
ITEM 4.	MINE SAFETY DISCLOSURE	22

PART II		23
ITEM 5.	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	23
ITEM 6.	SELECTED FINANCIAL DATA	24
ITEM 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	24
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	30
ITEM 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	30
ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	30
ITEM 9A.	CONTROLS AND PROCEDURES	30
ITEM 9B.	OTHER INFORMATION	31

PART III		32
ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE	32
ITEM 11.	EXECUTIVE COMPENSATION	35
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	36
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	37
ITEM 14.	PRINCIPAL ACCOUNTANT FEES AND SERVICES	38

PART IV		39
ITEM 15.	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	39

SIGNATURES		43

FINANCIAL STATEMENTS		44

Table of Contents

FORWARD-LOOKING STATEMENTS

Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements involve risks and uncertainties, including, among other things, statements regarding our business strategy, future revenues and anticipated costs and expenses. Such forward-looking statements include, among others, those statements including the words “expects,” “anticipates,” “intends,”, “plans,” “may,” “could,” “should,” “likely,” “believes” and similar language. Our actual results may differ significantly from those projected in the forward-looking statements. You should carefully review the risks described in this Annual Report and in other documents we file from time to time with the Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. We undertake no obligation to publicly release any revisions to the forward-looking statements or reflect events or circumstances after the date of this document.

Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements.

Factors that might cause or contribute to such differences include, but are not limited to, those discussed below and in the sections “Business,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Factors that may cause actual results, our performance or achievements, or industry results, to differ materially from those contemplated by such forward-looking statements include without limitation:

1.	Our ability to successfully engage, through our majority owned subsidiary, Bio AMD Holdings Limited, in the Point Of Care medical diagnostic device business including:

a)	Acceptance of our technologies or future technologies in the marketplace,

b)	Demand for products or future products that utilize our technologies,

c)	Our ability to secure license or profit sharing related agreements and secure government research and development grants,

d)	Our ability to successfully conduct laboratory and clinical testing of our potential products working with our partners; and

e)	Our ability to obtain regulatory approval of our future products.

2.	Our ability to successfully commercialize, through our majority owned subsidiary, WOCU Limited, our currency risk mitigation product, the WOCU®, and that proposed applications involving the WOCU product have collateral effects which render the application undesirable or unmarketable;

3.	The intensity of competition in both industries in which our subsidiaries operate; e.g. that known or unknown competitors may develop products with similar applications to our proposed products, which may prove to be superior in performance and/or price to our products;

4.	Our ability to raise additional capital as and when needed on acceptable terms;

5.	General economic conditions that affect the industries or the global environment in which we operate; and

6.	Our ability to successfully attract and retain management and other key employees.

All references in this Form 10-K to the “Company,” “we,” “us” or “our” are to Bio-AMD, Inc. and, unless otherwise differentiated, its subsidiaries, Bio AMD Holdings Limited and WOCU Limited.

Table of Contents

PART I

ITEM 1.

BUSINESS

Organizational History

We were incorporated in the State of Nevada under the name Malibu Minerals, Inc. on March 10, 2006, to engage in the business of exploration and discovery of gold, minerals, mineral deposits and reserves. On July 6, 2007, we changed our name to Flex Fuels Energy, Inc. through a merger effected for that sole purpose. On April 15, 2011, we changed our name to Bio-AMD, Inc. through a merger effected for that sole purpose.

During the fourth quarter of 2006, we acquired a 15% interest in Flex Fuels Energy Limited (“FFE Ltd.”). In May 2007 we completed the acquisition of the remaining 85% of FFE Ltd., making FFE Ltd. a wholly owned subsidiary of ours. FFE Ltd., a development stage company, was formed on November 26, 2006 under the laws of England and Wales to engage in the business of manufacturing and distributing oil seed rape (“OSR”) products. Effective June 5, 2009, we determined to abandon FFE Ltd.’s proposed oil seed business and related projects as we no longer considered the business to be economically viable on either a go alone or partnered basis. FFE Ltd was formally dissolved in February 2011 and the final winding down accounting transaction took place in May 2011.

On May 1, 2009, we acquired stock of WDX Organisation Limited, a corporation incorporated under the laws of England and Wales representing a 51% interest in the company. Since such time, we have acquired additional stock of WDX Organisation Limited and as of December 31, 2015 owned 99.81% of WDX Organisation Limited making it a majority owned subsidiary of ours. WDX Organisation Limited is the developer of a technology designed to mitigate currency risk. WDX Organisation Limited changed its name to WOCU Limited (“WL”) effective January 29, 2013. See “Item 1. Business – Business Overview – WL Currency Risk Mitigating Business”.

On February 25, 2010, we entered into a Subscription and Shareholders Agreement with Bio AMD Holdings Limited (“Bio-AMD”), a UK limited company, and the managers of Bio-AMD, under which we acquired 63% of the fully diluted equity in Bio-AMD for £865,000 GBP (approximately US$1,335,000 at the time of purchase). Bio-AMD is a technology company focused in the rapidly expanding global medical diagnostic Point Of Care (“POC”) market. See “Item 1. Business – Business Overview – Bio Alternative Medical Devices.”

On December 24, 2011, we sold the mineral licenses and associated rights over the “Malibu Gold Property” which was originally acquired on March 27, 2006 to engage in the business of exploration and discovery of gold, minerals, mineral deposits and reserves. Our rights and licenses were held via a trust agreement dated November 28, 2007 between the Company and Mr. James Laird, formerly a Director of the Company, in which the Company was deemed to have a beneficial interest, since non-Canadian entities are prohibited from holding such licenses directly. The claims were sold for gross proceeds of 20,000 Canadian Dollars (approximately US$20,167 at the time of payment), subject to a commission payable of 15% equivalent to 3,000 Canadian Dollars (approximately US$3,025 at the time of payment), to Mr. Laird who served as broker in the transaction.

Our fiscal year end is December 31. Our consolidated financial statements are prepared in accordance with United States Generally Accepted Accounting Principles, in United States dollars. Amounts stated in other currencies have been translated for the convenience of the reader at historical rates then prevailing.

Business Overview

During the fiscal year ended December 31, 2015, we were engaged in the following sectors:

●	developing our POC medical diagnostic device business; and

●	commercializing our WOCU based currency risk mitigation business.

We will require additional funding in the future for the full implementation of our business plans as described in this report.

Our Strategy

Since May 2009, we have acquired stock resulting in the majority ownership of two potential high growth businesses, which we believe can create shareholder value:

●	Bio-AMD, a company of which we own 63%, is a medical technology company focused in the rapidly expanding POC medical diagnostic market.

Table of Contents

●

WL, a company of which we own 99.81%, has developed the WOCU, a derivative quotation designed to mitigate currency risk, that can be licensed into a wide variety of corporate and retail financial based products including, but not limited to, exchange traded funds, indexed structured products and derivatives.

During fiscal year 2016, we will continue to develop and attempt to commercialize our products with the objective of creating sales revenue from these operations. This will necessitate the use of funds from our available cash balances, and will also require us to raise additional funds to support our overhead and future growth plans. Bio-AMD is the primary focus of our operations.

The Company is a speculative investment, and investors may lose some or all of their investment in the Company.

Operations – Bio Alternative Medical Devices

On February 25, 2010, we entered into a Subscription and Shareholders Agreement with Bio-AMD, and the managers of Bio-AMD, under which we acquired 63% of the fully diluted equity in Bio-AMD for £865,000 (approximately US$1,335,000 at the time of purchase). The purchase price was applied to the Bio-AMD business to commence its business plan. The 37% of Bio-AMD not owned by us is owned by Dr. Nasser Djennati (12.33%), Dr. Andrew Mitchell (12.33%) and Robert Galvin (12.33%), our Chief Financial Officer. Bio-AMD was formed in February 2010 and primarily operates through its wholly owned subsidiary, Bio Alternative Medical Devices Limited (“Bio-Medical”), a United Kingdom corporation. Where context requires, reference to Bio-AMD also includes reference to Bio-Medical.

Technology – overview

The trend toward greater POC testing is driven by the faster diagnostic benefits it provides. Other reasons have also emerged for the high demand of POC testing, including clinical staff shortages, an ageing population, long-term healthcare cost savings and a decrease in reliance on conventional laboratory services.

We believe that Bio-AMD is an innovator in the field of diagnostic sensor technology, with the attributes of its technology platform fitting well with these key trends.

· A disposable micro-fluidic test strip which has been adapted to measure prothrombin time (PT/INR) and designed to be capable of performing additional coagulation related tests such as APTT and DTI, through a POC blood coagulation monitoring device (“COAG”) enabling patient based, anticoagulant drug therapy monitoring;

· A Digital Strip Reader (“DSR”) able to read a wide variety of lateral flow based immunoassay diagnostic test strips already in the POC market including, but not limited to, cardiac markers, infectious diseases, drugs of abuse and female wellbeing (pregnancy/ovulation testing) to provide semi-quantitative results; and

· A disposable test strip combining micro-fluidics and ‘lab-on-chip’ technology providing fully quantitative measurement into a highly sensitive and accurate immunoassay POC platform that detects nanoparticles through magnetic manipulation using a novel magnetic and optical double detection technique – Magnetic Immunoassay Detection System (“MIDS”).

COAG

Bio-AMD’s micro-fluidic strip technology has been applied for use in a POC hand-held device to detect prothrombin time (“PT”)/International Normalized Ratio (“INR”), or the speed of blood coagulation. In 2013, the POC coagulation market for PT/INR measurement was estimated to be worth approximately US$ 870 million globally and projected to grow to an estimated US$ 1.1 billion by 2017. Market growth is driven by the rising number of patients using anti-coagulation therapy, growing clinical evidence supporting the use of such testing and strong patient demand for patient self-testing. The market is dominated by a small number of major players including Alere, Roche, Siemens and Philips who have either developed products internally or have acquired exclusive rights to license appropriate technologies from smaller companies. Patients with cardiac problems are often on life-long oral anticoagulation therapy, for example Warfarin. Frequent testing and careful monitoring of the PT/INR or blood coagulation to regulate the doses of anticoagulation therapy is a necessity. A patient taking too much anticoagulant is at risk of serious bleeding events and if too little is taken they may be at risk of thrombosis. PT/INR measurement products currently in the market are often cited as being expensive and complicated to use.

Bio-AMD has established a design that allows for low cost manufacture of the disposable strip whilst ensuring scalability and repeatability. We have performed extensive in-house bench tests at our laboratory and further tested in an initial hospital study producing comparable results to the current ‘best in market’ devices, which we believe validates the feasibility of our design.

Table of Contents

In late 2013, we filed a patent application for a multi-chamber microfluidic strip design, incorporating a novel locking mechanism that allows for the control of fluid flow through the strip. In addition to being able to test for PT/INR which requires the presence of a single reagent in the immunoassay testing process this enhanced strip design enables additional coagulation based tests requiring the use of multiple reagents in the immunoassay process, e.g. Activated Partial Thromboplastin Time (“APTT”), a laboratory based test used to measure the activity of direct thrombin inhibitors.

In June 2015 Bio AMD Holdings Limited received notice of the grant of a U.S. patent dated June 2, 2015, under U.S. Patent No. US 9,046,512 protecting twenty one claims central to the Company’s microfluidic strip and reader technology designed to test PT/INR by a POC device.

We plan to apply the new strip design to multiple, different coagulation specific tests utilizing a common hand held reader device to display the results. For example, a clinician testing for PT/INR would use a specific PT/INR strip and record the result from the reader. The clinician would then be able to test for APTT using a separate APTT specific strip using the same reader device. The test strips would use a common plastic component design, which we believe will reduce overall production costs.

Launching a product into the coagulation market that incorporates our COAG technology will require us to partner with a much larger, suitable business with the requisite capital resources and skills including distribution and sales channels, and ideally global marketing expertise in sectors such as hematology and immunochemistry. Our strategy for commercialization of COAG has centered on attracting a suitable partner that fits this profile, and which is keen to add a coagulation based POC system to its existing product line.

On December 17, 2014, we entered into a Master Agreement (the “Agreement”) with Sysmex Corporation (“Sysmex”) pursuant to which the parties will jointly conduct a feasibility study (the “Study”) for the potential development of our POC COAG system including a reader device with disposable test strips for PT-INR assays and potentially new future assays in the field of hemostasis (the “Products’). The results of the Study will form the basis on which we will negotiate with Sysmex the terms and conditions of possible future terms for further development of the Products (the “Research”). Under the terms of the Agreement, Sysmex will own all new intellectual property developed by either party in connection with the Study, and will reimburse Bio-AMD Ltd. for costs and expenses incurred in connection with the project development. An expense advance of £642,067 (approximately $980,000) was made to Bio-AMD Ltd. on January 20, 2015. If Sysmex determines the feasibility study to be successful and decides to progress with the Research, further cost reimbursements will be made during the term of the Agreement linked directly to milestone criteria and deliverables to be agreed by both parties.

The Agreement will terminate after 27 months or upon completion of the Research, whichever is earlier, and may be terminated by (i) Sysmex upon one month’s notice to Bio-AMD Ltd. and (ii) Bio-AMD Ltd. upon three month’s written notice to Sysmex.

During the term of the Agreement, both parties intend to determine the terms under which Bio-AMD Ltd. will either manufacture the Products or license its intellectual property, upon which any new intellectual property developed by either party in connection with the Study will be based, to allow the third-party manufacture of the Products, and for the terms under which Sysmex acquires the manufactured Products and its commercial resale.

The Study has been successfully completed and the results presented to Sysmex which is now clarifying the plan for the next phase of development. There can be no assurance that Sysmex will enter into additional agreements to jointly develop with us the Products or that such a manufacturing/license agreement will ever be consummated or that the Products will ever be commercially sold by Sysmex.

DSR

The DSR technology platform utilizes a patented proprietary method for reading and quantifying traditional chromatography based, nitro-cellulose, lateral-flow immunoassay tests, centered on what we believe to be a unique optical sensor arrangement. The DSR technology comprises a proprietary design incorporating sensors, diagnostics, display and power management capabilities. A key feature of the DSR technology is that its platform can be adapted and applied to numerous and disparate lateral flow diagnostic tests.

Bio-AMD has created designs for both single and multi-test versions of the DSR hand-held reader device and laboratory based bench tests have been performed by us in our premises using a variety of third party lateral flow strips. The DSR device is designed to be fully disposable and can be powered by solar power cells, although traditional battery power sources can also be used. Our multi-test device utilizes a replaceable cap system in which a new test strip is fitted, thereby enabling the hand-held reader to be used multiple times for the same test. By way of example, existing over the counter (“OTC”) home fertility testing packs normally contain up to 20 separate identical tests; for this fertility application our device would require just one reader device with 20 caps, each cap containing the test strip, thereby reducing the number of component parts and manufacturing cost.

Table of Contents

The market for female wellbeing, which includes digital home pregnancy and fertility testing, was estimated to be worth approximately $1.5 billion globally in 2012. Whilst the market for pregnancy testing is very competitive and dominated by a small number of large global brands e.g. Clearblue, Predictor and First Response, in several regions, particularly Asia, there is demonstrated demand from local distributors for OEM produced digital pregnancy test kits (“PTK”), the key factors being price and marketability by way of unique product features. Options for DSR might include creating our own branded and/or OEM digital pregnancy testing kit, or partnering with a qualified distributor aiming to launch a branded product into the region. This will entail our finalizing a product manufacturing design file and obtaining appropriate territorial regulatory approval specifically for the Asian market. Such a strategy will require additional capital, which we cannot guarantee would be available on terms acceptable to us or at all.

We have also been exploring, at an early stage, the potential to add value to diagnostic screening campaigns led by the National Health Service (“NHS”) in the UK. We are currently developing an approach to provide fully integrated, remote HIV based screening services, working with a partner. Utilizing a disposable diagnostic test, an individual patient case may be securely tracked from patient request and subsequent sample receipt through to patient result handling and treatment as required. A similar screening approach adopted in other STD testing by the NHS has seen both an increased number of screens and a higher diagnostic rate as targeted by the NHS. Discussions are at an early stage, and, if successful, may involve us providing a small number of units for a pilot scheme approved by the NHS and working closely with a partner to provide other aspects of the integrated service. Approval for such a scheme by the NHS cannot be guaranteed.

MIDS

Demand is increasing for POC tests that can detect very low concentrations of a target analyte and to quantify the result. Current lateral flow based immunoassays can detect analyte at high levels of concentration. However, at low concentration levels, the assay system requires amplification either of the signal or the target, which will typically increase the complexity and the costs of the testing device. Consequently, current POC tests remain largely unreliable for targets that require quantification.

We believe there to be an opportunity to develop a universal immunoassay based POC testing system which:

●	Is capable of detecting biomarkers at a nanoparticle level, providing fully quantitative measurement of results i.e. giving a numerical value for each biomarker detected and not just an indication on whether a specified biomarker is actually present,

●	Is capable of multiplexing i.e. performing multiple types of test from the same sample,

●	Provides full connectivity and networking for collection, storage and transfer of data and results,

●	Displays test results in minutes (less than 8 minutes for a panel of up to 3 tests),

●	Requires a finger prick sample size for a single test,

●	Utilizes a handheld reader and single disposable cartridge designed to be operated by a minimally trained person, requiring modest manual operation, other than for sample collection,

●	Contains all necessary reagents and where all steps are automated into an integrated encompassing pre-treatment, analyte specific reaction, signal production, signal reaction and final result: from sample to result in one step,

●	Can be adapted to perform different immunoassays for testing in areas such as infectious diseases, drugs of abuse or oncology, especially where rapid diagnosis is critical, and

●	Has a simple system design, requiring minimal direct input costs and inline manufacturing processes to keep unit costs as low as possible.

The technology will incorporate what we believe to be a novel microfluidic strip design, magnetic nanoparticle manipulation and a unique double detection technique using bespoke ‘Hall Effect’ sensors and bespoke optical sensor which, when combined, will increase significantly the sensitivity and accuracy of the result. We are not aware that this method is being used in products currently being offered in the market or in development.

We plan to develop the immunoassay platform initially for the cardiac marker POC testing market, which are measured to evaluate heart function. Cardiac markers are used in the diagnosis and risk stratification of patients with chest pain and suspected acute coronary syndrome. The detection of these markers is used to diagnose myocardial infarction and its severity, typically troponin (cTnI or cTnT), myoglobin and Creatine kinase MB isoenzyme (CK-MB). Our ultimate aim is to commercialize a product for the multiple cardiac marker testing market currently estimated by BCC Research to be worth US $1.3 billion globally in 2013 (including device, reagent and supply sales), and is expected to rise to $2.4 billion by 2018.

Additionally, we envisage the technology platform to be adaptable and be extended into new test areas, e.g. infectious diseases, drugs of abuse and oncology; having potential to expand into a multifunctional device, i.e. one analyzer using different strips for different tests; and can be introduced into high growth areas such as companion diagnostics (where POC devices are used to optimize the personalized dosage of a therapeutic drug).

Table of Contents

We believe that our MIDS technology has considerable potential to create a next generation of POC test devices. Our proposed method aims to bring together biology, chemistry, nano-fluidics, and electronics and, 'lab-on-chip' technology together into what we believe can be unique, economically viable products.

To date some very early stage work has been completed in conjunction with the Science, Technology and Facilities Council, one of Europe’s largest independent scientific research public body organizations in-part funded by the UK Government. This work has centered on the feasibility of our design and has proved successful. In April 2011 we made an initial patent application for the technology and in October 2012 we entered into the national phase stage, making applications in Europe, US, India and China.

In October 2014, the Company received a funding assistance award from Innovate UK, the UK’s Government supported innovation agency, in the amount of £23,326 ($36,655) for a “Proof of Market” report (“Report”) for our MIDS technology. A third party research company, Inventya Ltd., based in the UK, led an extensive market research project, working with us, into the potential for MIDS specifically into the cardiac marker POC testing market. The Report was received in May 2015 and includes a survey of key buyers, competitor analysis likely commercialization strategies. The Report concludes that strong potential opportunity exists for Bio-AMD’s MIDS technology to be applied to POC cardiac marker testing which would significantly accelerate the triage, diagnosis, treatment and disposition of patients. The Company plans to make further funding assistance applications across the various UK and EU grant schemes as and when suitable competitions arise.

Intellectual Property

Bio-AMD currently has nine patent applications pending covering its three proprietary technology platforms listed above. We continue to review our intellectual property strategy with the intention of sufficiently protecting our key intangible assets, and that any new IP generated is reviewed as far as possible to optimize the novel nature of the IP and freedom to operate in key jurisdictions.

In early 2016, the Company received a grant of patent from the State Intellectual Property Office of the People’s Republic of China (“PRC”) for our MIDS technology. The Company has made similar MIDS technology patent applications in the U.K. and in more than 145 Contracting States under the international Patent Cooperation Treaty, and separately in the U.S.A., European Union and India.

Patent costs are capitalized and included in our balance sheet under “Security deposits and Other assets”. As at December 31, 2015, capitalized patent costs amounted to £111,556 ($169,565). We will continue to file and prosecute patent applications when and where appropriate to attempt to protect our rights in our proprietary technologies.

The POC Market

POC testing includes any screening or diagnostic test that is performed outside the main hospital laboratory. Over the last decade, an increasing number of diagnostic tests have been performed at patients’ bedsides in hospitals, in physicians’ office laboratories, outpatient clinics, emergency rooms, and intensive-critical-care units. The wider availability of POC testing has revolutionized the continuum of the patient-care process by providing laboratory results rapidly and efficiently at these locations. It encompasses tests performed using bodily fluids such as blood, urine or saliva samples. A unique feature of POC technology is that it does not require interpretation by a trained laboratory professional, but is simple enough to be used by medical professionals or sometimes the patients themselves.

Where current practice dictates that a patient’s sample must be sent to a central laboratory for processing, POC testing can offer the potential for:

●	Significant savings in overall healthcare costs as a result of reduced patient waiting time, unnecessary hospital admissions and patient length of stay in hospital, and the increase in productivity of professionals through more rapid turnaround time.

●

Improvements for patient’s quality of life, e.g. avoidance of stress caused by uncertainty of their state of health or prognosis whilst a patient is awaiting results from tests – this is particularly relevant where patients provide a sample at a clinic, and then return when the tests results are ready which may be some days or weeks.

●	Earlier commencement of treatment, this may impact the outcome of treatment.

●	Error reduction.

Table of Contents

To be successful, POC tests must be clinically relevant, have a direct impact on patient management and outcome and be cost effective. Whilst a variety of POC technologies exist, many lack the required sensitivity and accuracy to provide fully quantitative measurement i.e. lab-quality results; some are lacking consistency, are expensive and in some cases require specific user training. The size of footprint of any system is important in determining its practical usefulness; many POC testing devices compete for space in crowded wards and surgeries, and therefore size of any device is paramount.

POC testing has the potential to dramatically change the way patients are treated, eventually to a point where patients are able to directly manage their own health for ongoing chronic conditions. Where rapid diagnosis is critical, POC testing can positively impact on the outcome of immediate and future treatment, improving considerably patient well-being.

According to a recent report from BCC Research, the global market for POC diagnostics, valued at $13.8 billion in 2011, is expected to increase to $16.5 billion in 2016. The market for POC diagnostics can be broken down into 10 segments: glucose monitoring, blood chemistry and electrolyte, pregnancy and fertility, cardiac markers, drug and alcohol, infectious disease, cholesterol, hemoglobin/hemostasis, urine chemistry and tumor marker.

The main trends in the POC market are:

Ÿ	Development of increasingly wide ranges of complex bio-chemical detectors and markers;

Ÿ	Increasing sophistication of smart strips to accommodate innovations in bio-chemistry; and

Ÿ	Increasing sophistication of readers, now regarded as both alternatives and complements to complex laboratory equipment.

POC diagnosis requires the combination of two main fields of science:

Ÿ	Bio-chemistry designed to detect changes in body fluid chemistry and signal a medical condition; and

Ÿ	Electro-mechanical engineering required to create apparatus to measure those chemical changes.

Successful delivery of POC diagnosis combines the following elements:

Ÿ	The biochemistry itself;

Ÿ	The medium that holds and combines the bio-chemistry with a body fluid sample; and

Ÿ	The device/reader that detects the changes in the biochemistry and communicates the result to the user/patient.

Reader technology development is focused on several key trends:

Ÿ	The miniaturization of the reader using low tolerance electronic and mechanical components;

Ÿ	Ease of use;

Ÿ	Reliability/accuracy/sensitivity;

Ÿ	Low manufacturing and end user cost; and

Ÿ	Self–powered operation for example incorporating solar power into the device.

We believe that Bio-AMD is an innovator in the field of reader technology development, with the attributes of its technology platform fitting well with these key trends.

Bio-AMD Business Model and Strategy

Bio-AMD’s current business model aims to commercialize its pipeline of technologies into diagnostic testing devices in conjunction with preferred partners. Target partners are those who we believe our technology will fit strategically within their existing portfolio either as a complement to a product line, as a replacement technology or as a new product initiative. The partner will have the requisite resource including sales and marketing, brand strength, distribution channels and balance sheet strength to take a product to market in tandem with us. We believe this strategy is especially relevant in the med-tech sector where larger players are better positioned to launch and gain acceptance and sales of new products, based on their extensive distribution and market intelligence of current needs.

Bio-AMD expects that its revenue model will include revenue sharing or royalty payments, licensing sales, and milestone awards from development partners, depending on the terms of the commercial agreement entered into. Our plan for the fiscal year ending 2016 is to continue in our attempts to secure commercial agreements for DSR for pregnancy and other applications, and to progress with the Agreement signed by Sysmex. We are also flexible towards the establishment of manufacturing capability, specifically for disposable strips, where quality and regulatory compliance are paramount. Having a captive manufacturing facility would enable us to maintain control over the quality and regulatory aspects of the strip, and would also potentially add significantly to sales revenues. However, we will only contemplate such moves where it makes economic sense to do so and where we believe significant value can be added to our business.

Table of Contents

In addition, the further work required on our MIDS platform will require additional capital if we decide to commence work on a full development project. Currently we are constrained from such activity by our limited working capital, expertise and resources, and it is unlikely that royalty and licensing revenues, if they materialize, will be sufficient to fund these growth plans. Any decision to undertake any significant development work in new testing areas of the POC market, enter into manufacturing or to further our work on the MIDS will require us to raise capital to fund those plans.

Bio-AMD continues to be alert to grant funding opportunities and tax based incentives primarily from the UK Government based initiatives and schemes, as and when they arise. Bio-AMD has been successful in applying for tax credits whereby computed tax losses in the UK entity are surrendered for cash at a pre-determined rate. To date we have applied for and successfully received a total of £204,741 (approximately $326,000) in cash payments for tax losses surrendered for the UK tax periods 2010-2014. We will continue to make such applications and opt for further cash payments for subsequent years, however there can be no assurance that we will be successful.

Since January 2014, the Company has provided additional working capital by way of cash injections via intercompany loans amounting to £100,000 (approximately $148,000 as of December 31, 2015) to Bio-AMD Holdings to further fund operations. These loans are secured against the assets of Bio-AMD Holdings and its wholly owned operating subsidiary Bio Alternative Medical Devices Ltd.

To date, no revenues had been generated by Bio-AMD Holdings.

Government Regulation

We anticipate that our partners with whom we enter into licensing contracts will assume responsibility for meeting the regulatory requirements of any of the diagnostic devices created utilizing our technology; though should we be required to fulfill any regulatory approvals, there can be no assurance that we will be able to comply with such laws or regulations.

The end user products that will incorporate our technology platforms will be subject to extensive and frequently changing federal, state, local and foreign laws and regulations. Many of the end-user applications for our technology are regulated in the U.S. as medical devices by the United States Food and Drug Administration ("FDA"). The FDA is responsible for enforcement of the Federal Food, Drug and Cosmetic Act, as amended, (“FDC Act”) which regulates drugs and devices manufactured and distributed in interstate commerce.

Any diagnostic products sold in the United States require either FDA clearance to market under Section 510(k) of the FDC Act, or Pre-market Approval, or PMA, which may require pre-clinical and clinical trials. Foreign countries may require similar or more onerous approvals to manufacture or market these products.

The marketing of consumer diagnostic products is also subject to regulation by the U.S. Federal Trade Commission, or the FTC. In addition, the end user product will be required to meet regulatory requirements in countries outside the United States, which can change rapidly with relatively short notice. It must also be demonstrated to the FDA that diagnostic tests intended for home use or for use by laboratories holding a Certificate of Waiver under the Clinical Laboratory Improvement Act of 1967 and the Clinical Laboratory Amendments of 1988, or CLIA, including most physician office laboratories, are simple with a low risk of error. Foreign countries may require similar or more onerous approvals to manufacture or market our products.

Failure to comply with applicable regulatory requirements can result in the refusal by regulatory agencies to approve product licensing. Non-compliance can also result in fines, criminal prosecution, recall or seizure of products, total or partial suspension of production, or refusal to enter into additional contracts.

Any regulatory clearances that are received for a product may be subject to limitations on approved uses for the product. After obtaining marketing clearance for any product, the manufacturer and the manufacturing facilities for that product will be subject to continual review and periodic inspections by the FDA and other regulatory authorities. If previously unknown problems with the product or with the manufacturer or facility are discovered, restrictions may be imposed on the product or manufacturer, including an order to withdraw the product from the market. If we, or any contract manufacturers we choose to engage, fail to comply with applicable regulatory requirements, we may be fined, sales of our products may be suspended or subject to withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

Liability Insurance Coverage

We anticipate that partners with whom we plan to license our technologies to and any third party sub-contract manufacturers used to manufacture products incorporating our technology will have their own products liability insurance coverage (under which we would be covered or indemnified against such liabilities).

Table of Contents

Bio-AMD Management

Bio-AMD is based at the Sci-Tech Daresbury (formerly the Daresbury Science and Innovation Campus) in Cheshire, UK, which is now a government designated Enterprise Zone. Sci-Tech Daresbury was formed as part of a UK government initiative to maximize the effects of public investment on business-science collaborations. Being based at Sci-Tech Daresbury means that Bio-AMD is able to access a network of government supported research facilities including expertise and resources which are based on site and collaborate with high profile government backed scientific bodies. To date, Bio-AMD has benefited from some small grant aid made available to it through various schemes offered throughout the campus network, and it continues to take advantage of the access afforded to it by the Science and Technologies Facilities Council, one of seven national research councils in the UK funded by the UK Government, which is located on the campus site.

Bio-AMD is managed by experienced personnel, expert in the development of technically advanced, low cost POC devices. Our Chief Financial Officer, Robert Galvin, is actively involved in the financial and commercial management of Bio-AMD and the execution of the Bio-AMD business plan. Mr. Galvin owns 12.33% of Bio-AMD directly.

Operations – WL - Currency Risk Mitigating Business

WL is the creator of a proprietary algorithm that produces a global currency derivative quotation known as the WOCU. The WOCU can be applied to financial products provided by third parties such as index structure products, exchange traded funds or derivate contracts, with a view to mitigating any currency risk inherent within those products. The WOCU algorithm was completed in June 2009, with further work including back-testing using historical foreign exchange data, to prove the attributes of the WOCU design, taking place throughout 2010. Since that time, the WL management team has sought to achieve licensing deals with a variety of financial institutions that are seeking to create financial products denominated in WOCU.

WL has not achieved any operating revenues to date and does not expect to achieve operating revenues until such time, if ever, that the WOCU is successfully marketed.

On May 1, 2009 we entered into an Investment Agreement (the “Investment Agreement”) with WL, and the founding shareholders of WL (the “Founders”), the owners of all of the issued and outstanding shares of WL. On the same date, we entered into a related Loan Agreement (the “Loan Agreement”) and a related Option and Funding Agreement (the “Funding Agreement”) with WL. The Investment Agreement, Loan Agreement and Funding Agreement are hereinafter collectively referred to as the “Agreements”. As of December 31, 2015and currently, we own 99.81% of the issued and outstanding share capital of WL on a fully diluted basis.

On July 21, 2010 we entered into a Deed of Variation of Loan Agreement with WL for the purpose of consolidating the outstanding loans (being a principal amount of £600,000 or approximately $915,000) made by us to WL.

On July 23, 2010 we entered into a Subscription Agreement with WL and the Founders under which we purchased 500,000 preference shares of WL (the “Preference Shares”) at a price of one British Pound per share or an aggregate of £500,000 (approximately $750,000) at the time of purchase. The Subscription Agreement also provided for WL to allot up to an aggregate of 16,900 C Ordinary Shares of WL to employees, directors and consultants of WL to secure their continued service to WL and incentivize them in the performance thereof. An aggregate of 14,061 C Ordinary Shares were issued, which reduced our ownership in WL from 93% to 77.54%.

Effective June 30, 2011, WL agreed with all three of its employees to terminate existing employment agreements so as to reduce the monthly cash outflows. As a result of the termination of employment contracts and in accordance with the WL Articles of Association terminated employees effectively gave up 9,243 C Ordinary Shares. This had the resultant effect of increasing our ownership in WL to 87.13% on a fully diluted basis.

During November 2011 we loaned an additional £50,000 to WL as a short-term unsecured intercompany loan. On July 12, 2012 it was agreed that this loan would be settled through the issuance to us of 5,000,000 ordinary shares, increasing our ownership in WL to 99.81%.

Since January 2013, the Company has provided further advances totaling £193,000 (approximately $312,650) into WL to fund its anticipated operations based on the prospective pipeline of opportunities that have been generated.

Effective January 29, 2013 WL changed its name to WOCU Limited from WDX Organisation Limited.

Table of Contents

WL’s product – the WOCU

The WOCU is a foreign exchange derivative quotation computed by our proprietary algorithm; a weighted currency basket encompassing the exchange rates of the fiat (national) currencies of the world’s twenty largest economies (currently accounting for around 81% of global production), weighted by the International Monetary Fund (“IMF”) Gross Domestic Product figures of those individual countries and outputted as daily and hourly reference prices.

The WOCU’s generally low volatility against fiat currencies offers huge commercial advantages as a unit of account for the denomination of world trade, compared to the status quo of cross border trade denominated in fiat currency pairs, or in US Dollars. Transactions across currencies (except in isolated cases where one exchange rate is “pegged” to the other) inevitably involve potential foreign exchange risk caused by movements in exchange rates. The advantage of denominating a transaction involving foreign exchange in WOCU is that it can lower the foreign exchange (“FX”) volatility as compared to traditional currency pairs.

The WOCU, subject to the achievement of the WL corporate strategy and business model described below, is expected to have application to:

· Multinational corporate treasury operations;

· Reference pricing for general global trade;

· Reference pricing for currency, fixing, including virtual, online currencies;

· Commodity pricing and trade;

· Currency balanced savings accounts;

· Fund management, including Exchange Traded Funds;

· FX and derivative trading and speculation;

· Global index calculations; and

· Reserve ratio applications (similar to the IMF’s Special Drawing Right or SDR).

The WOCU’s apolitical, bank-independent, transparent, instant availability and universal nature are believed to be a key differentiator compared to alternative methods of hedging against currency risk.

The WOCU quotation is calculated and published by WL as daily and hourly fixed reference prices for a total of 169 fiat currencies, digital currencies and commodities. In addition WOCU Foreign Exchange (“FX”) 1, 2, 3, 6, 9 and 12 month Forward quotations will be produced by WL against the USD, from which a Forward WOCU rate can be calculated for any currency for which Forward rates are currently quoted, plus WOCU Interest Rate forward quotations covering the Overnight 1, 2, 3, 6, 9 and 12 month money market periods. The WOCU reference price is fixed daily at 16:00 UTC against all major currencies and is also available as an hourly reference price, from 00:00 Monday to 23:00 Friday, and as hourly price captures for gold, silver and oil.

The WOCU quotation is available (non-exclusively) from WL’s re-seller Interactive Data Corporation (“IDC”) via its data terminals and data feeds under the ticker symbol XCU. IDC currently calculates and offers quotations for 47 WOCU based currency pairs, and 6 commodities, as cross rates and supplies a stand-alone WOCU real-time charting package application via IDC’s PrimePortal™ application. WOCU rates are also available on the professional Thompson Reuters platform and on the UK’s leading retail price data platform ADVFN.

The WOCU quotation is also available via a mobile application for Apple mobile devices known as “WOCU”. This application supports five languages; English, simplified Chinese, traditional Chinese, Japanese and Korean. The WOCU quotation is also available as an hourly reference price available directly from WL by RSS feed, e-mail and via WL’s FTP server. The WOCU quotation as an hourly updated price is also available from the Company’s corporate website www.wocu.com

WL has established relationships with a number of individuals and organizations authorized to serve as introducing agents (“IAs”) to the WL business, charged with identifying suitable prospects that fit the WL target profile. These IAs are remunerated purely on a contingent basis linked only to successful results and each IA generally is responsible for its own expenses. The exact terms of any IA arrangement is agreed between WL and the IA on a case by case basis. IAs are chosen based on their experience and knowledge of the financial markets and their deep contact network. To date six such IAs have been appointed and one is considered to be active.

Table of Contents

WL corporate strategy and business model

The core strategy of WL has been ultimately to market the WOCU across an inter-connected triumvirate group of 1) companies (who will trade and transact in the WOCU), 2) commercial banks (who would provide pricing and settlement of WOCU transactions into local currency), and 3) exchanges (who would provide products and instruments suitable for trading).

Specifically, WL plans to seek multiple revenue streams:

Ÿ	From / via users: reference, real time and historical data sales, to be distributed via global third party data distributors;

Ÿ	From banks: transaction fees and / or algorithm licensing fees; and

Ÿ	From derivatives exchanges: transaction fees and / or WOCU licensing fees.

Key partnerships and relationships in this regard fall broadly into these categories;

Ÿ	Data distribution;

Ÿ	Bank and FX Electronic Communication Networks (“ECN”) liquidity;

Ÿ	Derivative liquidity;

Ÿ	Commercial customers; and

Ÿ	Other platforms and opportunities.

WL’s initial intention was to simultaneously engage with a bank, a derivatives exchange and a large retail focused user in order to launch the tradable WOCU and associated products. To date we have not concluded any formal arrangements of this relatively complex nature.

Our commercial activities are undertaken by our active IAs chosen based on their experience and knowledge of the financial markets, and who have a deep client network to help promulgate the Wocu brand. In the event that a contract is agreed, commission is paid to the individual or organization the terms of which are to be agreed on an individual basis.

During March 2015, we received expressions of interest from parties considering utilizing the WOCU for cross border transactions as a unifying currency reference within international software platforms. We continue to explore and progress these opportunities as they may offer a simpler route to market and to establish use of the WOCU. However, there can be no assurance that we will conclude any formal arrangements for licensing or, if concluded, that we will generate a positive return on investment or provide operating revenues.

Since January 1, 2012, Mr. Michael Blakey, IT and Operations Director, has assumed leadership responsibility for WL. The Board of WL, which also serves as the operational management team, comprises Mr. Blakey, Mr. Thomas Barr and Mr. Robert Galvin. Messrs. Barr and Galvin also serve as directors of Bio-AMD, Inc. WL currently runs on a projected annual cash burn of £6,000, (approximately $9,200) per annum.

Malibu Gold Property

Property Acquisition Details

On March 27, 2006, we acquired a mineral license for the Malibu Gold Property from Mr. James Laird, a former director and stockholder, for $10,000. Since non-Canadian individuals or companies cannot directly hold mineral licenses in British Columbia, Mr. Laird held the license on our behalf under a trust agreement entered into on November 28, 2007. Since 2009, the property has been considered as non-core to our overall strategy, and we discontinued the development of the claims at that time, other than to re-stake one of the claims for a minimal fee that had expired so as to preserve value whilst we sought a buyer. On December 24, 2011, we sold the mineral licenses and associated rights over the “Malibu Gold Property” for gross proceeds of 20,000 Canadian Dollars (approximately US$20,167 at the time of payment), subject to a commission payable of 15% equivalent to 3,000 Canadian Dollars (approximately US$3,025 at the time of payment) to Mr. Laird who served as broker in the transaction.

Table of Contents

Discontinued Operation - FFE Ltd.

Effective June 5, 2009, after having evaluating all our options, we determined to abandon our proposed oil seed business to be conducted by our wholly owned subsidiary, Flex Fuels Energy Limited (“FFE Ltd.”) as we no longer considered the business to be economically viable on either a go alone or partnered basis. As a consequence of this decision to wind down the operations of FFE Ltd., we reported the results of FFE Ltd. as “discontinued operations” in the consolidated financial statements covered in this Annual Report for the year ended December 31, 2011. In addition, we have reclassified the historical operations of FFE Ltd. and its assets and liabilities as discontinued operations. As a result of the discontinuance of FFE Ltd.’s operations, we have removed our accumulated other comprehensive loss-foreign currency translation adjustment related to FFE Ltd. and recognized as loss on disposal/abandonment of investment in FFE Ltd. or as a liquidation of the investment in FFE Ltd. for the year ended December 31, 2011 under the caption, loss from discontinued operations. The effect of reporting FFE Ltd. as a discontinued operation is to effectively revert the consolidated financial statements back to those items associated with the parent company, reflecting mainly compliance related costs and movements in shareholder’s funds, and to the investments made into Bio-AMD and WL as described above.

On November 25, 2010 we filed to have FFE Ltd formally dissolved, having first assigned all rights to the Company. FFE Ltd was formally dissolved in February 2011 at which time there were no outstanding liabilities, and all existing assets had been transferred to the Company. The final winding down accounting transactions took place in May 2011.

Employees

As of December 31, 2015 neither the Company nor WL had any direct employees.

Bio-AMD has engaged three employed persons under service agreements containing terms and conditions which are in the normal course of business.

Effective August 29, 2012 WL entered into a consultancy agreement (the “Consulting Agreement”) with Grabling Services Limited through which the services of Mike Blakey (the “Consultant”) are provided. Mr. Blakey manages the WL business on a day to day basis. Under the Consulting Agreement Mr. Blakey was paid £2,500 per calendar month which has been amended to, as of May 1, 2015, to £500 per calendar month (approximately US $760).

Our Chief Executive Officer, Thomas Barr, is engaged by way of a Supply of Services Agreement entered into on July 1, 2009. Our Chief Financial Officer, Robert Galvin, is engaged on a part-time basis by way of a Supply of Services Agreement entered into on July 1, 2009 with The ARM Partnership (“ARM”), a partnership in which Robert Galvin is a partner. Our President, David Miller, is engaged on a part-time basis by way of a Supply of Services Agreement entered into on July 1, 2009.

Further details of the Supply of Services Agreements are provided in Item 10. Directors, Executive Officers, and Corporate Governance. We anticipate that we will be conducting most of our business through agreements with consultants and third parties. To the extent that we are successful in developing our businesses we may need to hire additional employees/contractors during the fiscal year ending 2016.

Reports to Security Holders

We file annual, quarterly and current reports and other information with the Securities and Exchange Commission. You may read and obtain copy of any reports, statement or other information that we file with the Commission at the Commission's public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the Commission at (202) 551-8090 for further information on the public reference room. These Commission filings are also available to the public from commercial document retrieval services and at the Internet site maintained by the Commission at http://www.sec.gov.

In addition our filings can be viewed on the “investor” section of our Internet site at www.bioamd.com.

ITEM 1A.

RISK FACTORS

You should carefully consider the risks described below as well as other information provided to you in this Annual Report, including information in the section of this Annual Report entitled "Information Regarding Forward Looking Statements." The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also impair our business operations. If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected, and you may lose all or part of your investment.

Table of Contents

RISKS RELATED TO OUR FINANCIAL RESULTS

Investing in our shares involves a high degree of risk. Before you invest in our shares, you should understand the high degree of risk involved. You should carefully consider the following risks and other information in this Form 10-K, including our financial statements and related notes appearing elsewhere in this Form 10-K, before you decide to invest in our shares. If any of the events described below actually occurs, our business, financial condition and operating results could be harmed. In such an event, the market price of our shares would likely decline and you could lose part or all of your investment.

We have incurred losses since our inception, have yet to achieve profitable operations and anticipate that we will continue to incur losses for the foreseeable future.

For our 2015 fiscal year, we incurred an operating loss of $911,423. In each of our prior fiscal years we have had an operating loss and carry a significant accumulated loss as a development stage company. We have generated no revenues to date from any of our operating segments. We plan to increase our expenses associated with the development of our Point Of Care (“POC”) diagnostics business and with the development of our currency risk mitigation business. Before we are able to achieve revenues that cover our operational expenses, we believe that there will have to be additional financing, substantial marketing, and product testing, among other things. There is no assurance we will be able to derive revenues from the exploitation of our POC diagnostics business or our currency risk mitigation business to successfully achieve positive cash flow or that our POC diagnostics business or currency risk mitigation business will be successful.

We believe that long-term profitability and growth will depend on our ability to:

Ÿ	develop and market our POC diagnostic business;

Ÿ	develop and market our currency risk mitigation business; or

Ÿ	engage in any alternative business.

Inability to successfully execute on any of the above, among other factors, could have a material adverse effect on our business, financial results or operations.

Because we have a limited operating history, have yet to attain profitable operations and will need additional financing to fund our businesses; currently our financial position reflects as doubt about our ability to continue as a going concern.

The consolidated financial statements for the year ended December 31, 2015 have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We have accumulated a loss to date and have relied on raising funds through private placements. From inception (March 10, 2006) to December 31, 2015 we raised approximately $18,977,000, net of placement costs, and at December 31, 2015 held $437,400 in cash. Our consolidated financial statements do not include any adjustments that might result from our inability to continue as a going concern.

As shown in the accompanying consolidated financial statements, we have not generated any revenue since March 10, 2006 (date of inception) to December 31, 2015. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The future of our Company is dependent upon our ability to obtain financing, to generate sufficient cash flow from our planned businesses and ultimately to obtain profitability. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence.

If we pursue the contemplated business development and expansion activities, we will require additional financing to fund our operations. We will seek such additional funds through private placements of our equity or debt securities or through loans from financial institutions, our directors or our stockholders. Currently, we do not have any arrangements in place for additional funding. There can be no assurance that we will be able to raise the additional funds needed, on terms acceptable to us or at all. If we do not obtain additional financing, when required, our planned business may fail.

Obtaining additional financing is subject to a number of factors, including investor acceptance of the value of our POC diagnostics business and our currency risk mitigation business. These factors may adversely affect the timing, amount, terms, or conditions of any financing that we may obtain or make any additional financing unavailable to us.

To date, our sources of cash have been primarily limited to the sale of our equity securities. We cannot be certain that additional funding via this means will be available on acceptable terms if at all. To the extent that we are able to raise additional funds by issuing equity securities, our existing stockholders may experience significant dilution. Any debt financing that we may secure, if available, may involve restrictive covenants that impact our ability to conduct our business. If we are unable to raise additional capital, when required, or on acceptable terms, we may have to delay or scale back significantly or discontinue our planned exploration and development projects. Inability to obtain these or other sources of capital could have a material adverse effect on our business, financial results or operations.

Table of Contents

RISKS RELATED TO OUR MANAGEMENT AND CORPORATE GOVERNANCE

We have no independent directors, which poses a significant risk for us from a corporate governance perspective.

Our three executive officers, namely Mr. Thomas Barr, our chief executive officer; Mr. Robert Galvin, our chief financial officer, and treasurer; and Mr. David Miller, our president and secretary, also serve as our three directors. Our directors and executive officers are required to make interested party decisions, such as the approval of related party transactions, their level of compensation, and oversight of our accounting function. Our directors and executive officers also exercise control over all matters requiring stockholder approval, including the nomination of directors and the approval of significant corporate transactions. We have chosen not to implement various corporate governance measures, the absence of which may cause stockholders to have more limited protections against transactions implemented by our board of directors, conflicts of interest and similar matters. Stockholders should bear in mind our current lack of corporate governance measures in formulating their investment decisions.

We may find it difficult to attract senior management in the absence of Directors and Officers Insurance.

We do not presently maintain directors and officers insurance. This may deter or preclude persons from joining our management or cause them to demand additional compensation to join our management.

We will need to increase our size, and may experience difficulties in managing growth.

We are a smaller reporting company with no direct employees as of December 31, 2015. WL had no employees as at December 31, 2015. Bio-AMD had three employees as of December 31, 2015. We hope to experience a period of expansion in headcount, facilities, infrastructure and overhead to develop our prospective currency risk mitigation and POC diagnostic businesses and to address potential growth and market opportunities. Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional independent contractors and managers. Our future financial performance and our ability to compete effectively will depend, in part, on our ability to manage any future growth effectively. Inability to manage future growth could have a material adverse effect on our business, financial results or operations.

Our business is headquartered in the United Kingdom and none of our directors are resident in the United States; accordingly it may be difficult to enforce any liabilities against them.

If an event occurs that gives rise to any liability on the part of our officers and directors who are not resident in the United States, including liabilities arising under the US securities laws, stockholders would likely have difficulty in enforcing such liabilities. Stockholders may not be able to obtain jurisdiction in the United States over such non-resident officers and directors, and any judgment obtained against such persons in the United States may not be recognized or enforceable in the foreign jurisdiction where such person's assets are located.

RISKS RELATED TO OUR POINT OF CARE DIAGNOSTIC BUSINESS

Bio-AMD is a start-up business. No assurance can be given that Bio-AMD can successfully achieve demand for its products and achieve profitability.

There is no certainty that Bio-AMD’s products will achieve market acceptance or that Bio-AMD will achieve revenues or ultimately operational profitability. Commercial relationships have to be developed with other market participants to deliver Bio-AMD products to market which cannot be guaranteed to be consummated in a timely fashion, if at all. Although we have had exploratory conversations with potential third party, commercial users of our products, these discussions have not yet resulted in any commercialization arrangements.

Government regulation plays a significant role in our ability to market our technologies in the medical and consumer markets.

Healthcare is heavily regulated by national and regional governments, both in the U.S. and other countries. The laws and regulations affecting healthcare change constantly, thereby increasing the uncertainty and risk associated with any healthcare related venture. Certain of applications of our technologies will be required to meet the government regulations by the FDA and other similar regulatory authorities in other countries. Failure to meet or to obtain the approvals from these government agencies will limit our ability to market our technologies to prospective clients. These laws and regulations are extremely complex and, in some cases, still evolving. If our operations are found to be in violation of any of the international, federal, state or local laws and regulations that govern our activities, we may be subject to the applicable penalty associated with the violation, including civil and criminal penalties, damages, fines or curtailment of our operations. Any action against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s time and attention from the operation of our business.

Table of Contents

We are dependent on our patents and other intellectual property right protections. The failure to obtain patent protection could have a material adverse effect on our business, financial condition and results of operations.

We seek to protect our intellectual property rights through a combination of patent filings, trademark registrations, confidentiality agreements and inventions agreements. However, no assurance can be given that such measures will be sufficient to protect our intellectual property rights. If we cannot protect our rights, we may lose our competitive advantage. Moreover, if it is determined that our products infringe on the intellectual property rights of third parties, we may be prevented from marketing or licensing our intellectual properties to others.

The failure to protect our patents, trademarks and trade names, may have a material adverse effect on our business, financial condition and operating results. Litigation may be required to enforce our intellectual property rights, protect our trade secrets or determine the validity and scope of proprietary rights of others. Any action we take to protect our intellectual property rights could be costly and could absorb significant amounts of our management’s time and attention. In addition, as a result of any such litigation, we could lose any proprietary rights we have. If any of the foregoing occurs, we may be unable to execute our business plan and investors could lose their investment.

Our intellectual properties may become obsolete if we are unable to stay abreast of technological developments.

The biomedical industry is characterized by rapid and continuous scientific and technological development. If we are unable to stay abreast of such developments, our technologies may become obsolete. We lack the substantial research and development resources of some of our competitors. This may limit our ability to remain technologically competitive.

Other companies could create a technology that competes effectively with our DSR, COAG and MIDS technologies, and we may be unable to capture market share in our markets. Our intended markets generally are dominated by very large corporations (or their subsidiaries), which have greater access to capital, manpower, technical expertise, distribution channels and other elements which would give them a competitive advantage over us when we begin to compete directly against them. It is possible that these and other competitors may implement new, advanced technologies before we are able to, thus affecting our ability to license our intellectual properties at profitable rates or at all.

We cannot assure investors that we will be able to achieve the technological advances to remain competitive and become profitable, that new intellectual properties will be researched, tested and developed, that anticipated markets will exist or develop for our technologies, or that any product or services incorporating our intellectual properties will not become technologically obsolete.

We may be liable for products liability claims for which we have no insurance.

Although we do not manufacture products, we plan to license our technologies to entities that have their own product liability insurance coverage under which we anticipate we will would be covered or indemnified against such liabilities. Notwithstanding our licensing arrangements, we may be sued for product liability if products incorporating our patented technologies injure the end user. In the event that we are sued on this basis, liability claims could require us to spend significant time and money in litigation and pay significant damages that are not covered by insurance. As a result, any of these claims, whether or not valid or successfully prosecuted, could have a material adverse effect on our business and financial results.

Our prospective business may suffer if we are unable to attract or retain talented personnel.

Our success will depend in large measure on the abilities, expertise, judgment, discretion, integrity and good faith of our management, as well as other personnel. We have a small management team, and the loss of a key individual or our inability to attract suitably qualified replacements or additional staff could adversely affect our business. Our success also depends on the ability of management to form and maintain key commercial relationships within the market place. No assurance can be given that key personnel will continue their association or employment with us or that replacement personnel with comparable skills will be found. If we are unable to attract and retain key personnel and additional employees, our business may be adversely affected.

Table of Contents

We are operating in a highly competitive market.

The development and marketing of medical products and devices is extremely competitive and our commercial opportunity will be reduced or eliminated if the size of the market opportunity is less than we expect. In many cases we will compete with entrenched multi-national corporations, such as Siemens, Alere, Philips, Roche, Beckman Coulter, Abbott Laboratories and others, all of whom have similar products already being manufactured and sold. Competitors range from development stage companies to major domestic and international companies, most of which have substantially greater financial, technical, marketing and human resource capabilities than we have, as well as established positions in markets, name brand recognition, and established ties with original equipment manufacturers (“OEMs”). These or other companies may succeed in developing products or technologies that are more effective than those being developed by us or which would render our products and technology obsolete or non-competitive in the marketplace.

The development of our products and technology is uncertain.

Our development efforts are subject to unanticipated delays, expenses or technical or other problems, as well as the possible insufficiency of funding to complete development. In addition to having the necessary funding, our success will depend upon our products and technologies being differentiated from similar products and technologies and then meeting acceptable cost and performance criteria and timely introduction into the marketplace. All of our proposed products and technologies may never be successfully developed, and even if developed, they may not satisfactorily perform the functions for which they are designed. Additionally, these products may not meet applicable price or performance objectives. Unanticipated technical or other problems may accrue which would result in increased costs or material delays in their development or commercialization. If development activities are unsuccessful, we may need to delay, reduce the scope of or eliminate some or all of our development programs and significant monies and management time invested may be rendered unproductive and worthless. Diagnostic devices must be tested for safety and performance in laboratory and clinical trials before regulatory clearance for marketing is achieved. Such studies are costly, time consuming and unpredictable. Clinical trials may not be successful and marketing authorization may not be granted which may result in us not being profitable, or trigger dissolution of partnerships or collaborative relationships. The outcome of early clinical trials may not be predictive of the success of later clinical trials. Failed clinical trials may result in considerable investments of time and money being rendered unproductive and worthless.

Additionally, unanticipated trial costs or delays could cause substantial additional expenditure that is not reimbursed by a partner, cause us to miss milestones which trigger a financial payment or cause us or a partner to delay or modify our plans significantly. This would harm our business, financial condition and results of operations.

Bio-AMD will rely on third parties to support product delivery.

Under the current business plan, Bio-AMD may not manufacture or self-distribute its products. Consequently, Bio-AMD may need to rely on third parties for the manufacture and distribution of its products on an ongoing basis. Any failure on their part would disrupt product delivery and availability. To the extent we are able to enter into collaborative or strategic arrangements with respect to our products, we will be exposed to risks and uncertainties related to those arrangements which we will attempt to manage, as far as possible, by contractual arrangement. However, the customer or partner will generally make the key decisions on product choice, regulatory approvals, product launch, product manufacture and marketing and promotion. Decisions made by our partner with respect to the commercialization of the products we develop with them will significantly affect the extent and timing of revenues to us. For example, our partner may choose not to launch new products we develop, may choose to launch the products in a limited number of jurisdictions, may delay the launch of products, may undertake only limited sales and marketing efforts to commercialize the products, all of which would have a material adverse effect on our business and financial position. Collaborative arrangements, licensing agreements or strategic alliances will subject us to a number of risks, including the risk that:

we do not control the amount and timing of resources that our strategic partners may devote to our products;

we do not control the decision to pursue or amend a product, the timing of development activities, product launches and extent of marketing and sales activities;

our partners may experience financial difficulties;

business combinations or significant changes in a partner’s business strategy may also adversely affect a collaborator’s willingness or ability to complete its obligations under any arrangement;

a collaborator could independently move forward with a competing product developed either independently or in collaboration with others, including our competitors; and

collaborative arrangements are often terminated or allowed to expire, which would delay the development and may increase the cost of developing our products.

Table of Contents

Our products and technologies will depend on their compatibility and adaptability to third party designs.

Our success will depend upon our ability to make our products compatible with the products of third-party manufacturers. In addition, we will depend on potential customers redesigning or otherwise modifying their products to fully utilize our products and technologies. Our failure to make our products and technology compatible with products of third-party manufacturers or the failure of potential customers to make necessary modifications to or redesign their products to accommodate our products could have a material adverse effect on our ability to sell or license our technologies and products.

We have limited manufacturing and marketing experience.

Achieving marketing acceptance for our technologies and proposed products will require substantial marketing efforts and expenditure of significant funds to educate key original equipment manufacturers, or OEMs, as to the distinctive characteristics and anticipated benefits of our products and technologies. We currently have limited manufacturing and marketing experience and limited financial, personnel and other resources to undertake the extensive marketing activities that are necessary to market our products and technologies.

Our products may contain design defects.

Our products may contain design deficiencies or outright defects that become apparent subsequent to widespread commercial use. Remedying such issues could delay our plans and cause us to incur additional costs which would have a material adverse effect on our financial position. These design deficiencies or defects may result in harm to the users, for which we may be made liable. Such liability would have an adverse effect on our product acceptance, reputation and financial position.

We may not be able to manage growth and expansion effectively.

Rapid growth of our business may significantly strain our management, operational and technical resources. If we are successful in obtaining rapid market penetration of our products, we will be required to manufacture and deliver large volumes of quality products to our customers on a timely basis at a reasonable cost. Our strategy is to create partnerships with manufacturers. This could potentially strain our operational, management and financial systems and controls.

RISKS RELATED TO THE WL BUSINESS

WL is a start-up business. No assurance can be given that WL can successfully license the WOCU to third parties and achieve profitability.

There is no certainty that the WOCU can be licensed or that WL will achieve profitability. In particular a factor critical to the successful establishment of the WOCU would ideally be the willingness of several financial market participants, including one or more banks, to provide sufficient liquidity in the WOCU or its constituent currency pairs in WOCU proportionality. In addition commercial relationships have to be developed with other senior market participants to deliver WOCU products to market which cannot be guaranteed to be consummated in a timely fashion, if at all.

WL’s lack of product diversity subjects the Company to substantial risk.

Presently, the sole product of WL is the WOCU. This lack of product diversity subjects the Company, as well as WL, to substantial market risk from reliance on the success and revenues upon commercialization of a single product.

A competing product may be launched by a larger, more established competitor.

A competitor may produce a similar product that gains general traction in our target market, making it hard for the WOCU to compete. Such a competitor would likely be financial institutions with far greater financial support and backing, which may facilitate the sale of its product in a more timely fashion than WL is able to achieve.

WL relies on third parties to create and support tradable WOCU product delivery.

WL does not plan on supporting the end to end delivery of the WOCU trading product in-house. WL will rely on third parties, ideally several financial market participants, including one or more banks, for the delivery of WOCU liquidity, data and pricing mechanisms and therefore will be reliant on their ability and willingness to do so on an ongoing basis. Any failure on their part would disrupt product delivery and availability.

Table of Contents

RISKS RELATING TO OUR COMMON STOCK

We are subject to compliance with securities law, which exposes us to potential liabilities, including potential rescission rights.

We have periodically offered and sold our common stock to investors pursuant to certain exemptions from the registration requirements of the Securities Act, as well as those of various state securities laws. The basis for relying on such exemptions is factual; that is, the applicability of such exemptions depends upon our conduct and that of those persons contacting prospective investors and making the offering. While we believe that such exemptions were applicable to offers and sales of our common stock, we have not received a legal opinion to the effect that any of our prior offerings were exempt from registration under any federal or state law. Instead, we have relied upon the operative facts as the basis for such exemptions, including information provided by investors themselves.

If any prior offering did not qualify for such exemption, an investor would have the right to rescind its purchase of the securities if it so desired. It is possible that if an investor should seek rescission, such investor would succeed. A similar situation prevails under state law in those states where the securities may be offered without registration in reliance on the partial pre-emption from the registration or qualification provisions of such state statutes under the National Securities Markets Improvement Act of 1996. If investors were successful in seeking rescission, we would face severe financial demands that could adversely affect our business and operations. Additionally, if we did not in fact qualify for the exemptions upon which we have relied, we may become subject to significant fines and penalties imposed by the SEC and state securities agencies.

Additional capital funding will dilute the ownership interest of investors.

We will require additional capital to fund our future business operations. If we raise additional funds through the issuance of equity, equity-related or convertible debt securities, these securities may have rights, preferences or privileges senior to those of the rights of holders of our common stock, who may experience dilution of their ownership interest of our common stock. We cannot predict whether additional financing will be available to us on favorable terms when required, or at all. Since our inception, we have experienced negative cash flow from operations and expect to experience significant negative cash flow from operations in the future. The issuance of additional common stock by our board of directors may have the effect of further diluting the proportionate equity interest and voting power of holders of our common stock.

Our common stock is traded on OTC Markets (Ticker: BIAD.QB) and our shares are characterized as a penny stock. As such, we are subject to the risks associated with "penny stocks". Regulations relating to "penny stocks" limit the ability of our stockholders to sell their shares and, as a result, our stockholders may have to hold their shares indefinitely.

Our common stock is deemed to be "penny stock" as that term is defined in Regulation Section 240.3a51-1 of the Securities and Exchange Commission. Penny stocks are stocks: (a) with a price of less than U.S. $5.00 per share; (b) that are not traded on a "recognized" national exchange; (c) whose prices are not quoted on the NASDAQ automated quotation system (NASDAQ - where listed stocks must still meet requirement (a) above); or (d) in issuers with net tangible assets of less than U.S. $2,000,000 (if the issuer has been in continuous operation for at least three years) or U.S. $5,000,000 (if in continuous operation for less than three years), or with average revenues of less than U.S. $6,000,000 for the last three years.

Section 15(g) of the United States Securities Exchange Act of 1934 and Regulation 240.15g(c)2 of the Securities and Exchange Commission require broker dealers dealing in penny stocks to provide potential investors with a document disclosing the risks of penny stocks and to obtain a manually signed and dated written receipt of the document before effecting any transaction in a penny stock for the investor's account. Potential investors in our Common Stock are urged to obtain and read such disclosure carefully before purchasing any common shares that are deemed to be "penny stock".

Moreover, Regulation 240.15g-9 of the Securities and Exchange Commission requires broker dealers in penny stocks to approve the account of any investor for transactions in such stocks before selling any penny stock to that investor. This procedure requires the broker dealer to: (a) obtain from the investor information concerning his or her financial situation, investment experience and investment objectives; (b) reasonably determine, based on that information, that transactions in penny stocks are suitable for the investor and that the investor has sufficient knowledge and experience as to be reasonably capable of evaluating the risks of penny stock transactions; (c) provide the investor with a written statement setting forth the basis on which the broker dealer made the determination in (ii) above; and (d) receive a signed and dated copy of such statement from the investor confirming that it accurately reflects the investor's financial situation, investment experience and investment objectives. Compliance with these requirements may make it more difficult for investors in our common stock to resell their shares to third parties or to otherwise dispose of them. Stockholders should be aware that the market for penny stocks is susceptible to patterns of fraud and abuse. Such patterns include:

(i)	control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer;

(ii)	manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases;

Table of Contents

(iii)

boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons;

(iv)	excessive and undisclosed bid-ask differential and mark-ups by selling broker-dealers; and

(v)	the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the resulting inevitable collapse of those prices and with consequent investor losses.

Although we are not in a position to dictate the behavior of the market or of broker-dealers who participate in the market, management will strive within the confines of practical limitations to prevent the described patterns from being established with respect to our securities.

Adverse economic conditions may harm our business.

Market and economic conditions have been challenging worldwide. Continuing concerns have led to increased market volatility and diminished expectations for world economies. These factors may include fluctuations in foreign exchange rates, inflation, interest rates, rate of economic growth, taxation laws, consumer spending, unemployment rates, government fiscal, monetary and regulatory policies and consumer and business sentiment. Any of these factors have the potential to cause costs to increase or revenues to decline. Continued turbulence in the international markets and economies may adversely affect our ability to enter into or maintain collaborative arrangements, the behavior and financial condition of our current and any future customers and partners and the spending patterns of users of the products we are developing. This may adversely impact demand for our services and for products developed by us.

The price of our shares is highly volatile and could decline significantly.

The price of our shares is highly volatile and could decline significantly. The market price of our shares historically has been, and we expect will continue to be, subject to significant fluctuations over short periods of time. Some of the factors that may cause the market price of our common stock to fluctuate include:

the entry into, or termination of, key agreements, including key collaboration agreements and licensing agreements;

the extent of our ability to publically disclose sensitive information due to confidentiality restrictions placed upon us by collaborative partners;

third party disclosures out of our control and critical of the Company, its strategy, or our management;

any inability to obtain additional financing on favorable terms to fund our operations and pursue our business plan;

future sales of our common stock or debt or convertible debt securities or other capital-raising activities, and the terms of those issuances of securities;

future revenue streams from product sales, if any, by our collaborative partners, and the extent of demand for, and sales of, our products;

the initiation of material developments in, or conclusion of litigation to enforce or defend any of our intellectual property rights or otherwise;

our results of operations and financial condition, including our cash reserves, cash burn and cost level;

general and industry-specific economic and regulatory conditions that may affect our ability to successfully develop and commercialize products;

the loss of key employees;

the introduction of technological innovations or other products by our competitors;

sales of a substantial number of shares of our common stock by our large stockholders;

changes in estimates or recommendations by securities analysts, if any, who cover our common stock;

issuance of shares by us, and sales in the public market of the shares issued, upon exercise of our outstanding warrants; and

period-to-period fluctuations in our financial results.

Table of Contents

ITEM 1B.

UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

We occupy our premises, which we use as our administrative and management offices, by means of the following rental arrangements:

One of these offices previously served as the Company’s primary business address and is located at 3rd Floor, 14 South Molton Street, London, W1K 5QP, UK, comprising office space and meeting rooms in central London. The lessee of these premises is the ARM Partnership (Robert Galvin, our Chief Financial Officer, is a Partner of that partnership). The Company has had use of the office space for internal, board and third party meetings and document storage. The rental charge for use of the premises by the Company was set at £500 per month for Bio-AMD Inc. (approximately $760), this ceased on July 31, 2015 and £750 per month for Bio-AMD Holdings (approximately $1,150), reduced to £500 (approximately $760) for each of the months of August and September, 2015, and which ceased on September 30, 2015.

Bio-AMD occupies office and laboratory space at Sci-Tech Daresbury (formerly the Daresbury Science & Innovation Campus) in Cheshire, UK. The term of the rental agreement is for a fixed period of 3 years from August 1 2014. The rental charge is currently set at £2,562 (approximately $3,900), per month. The lessor may terminate the agreement by providing at least two months written notice to the tenant and the tenant may terminate the agreement by providing at least three months’ written notice to the landlord. We do not own any real estate.

ITEM 3.

LEGAL PROCEEDINGS

Legal Proceedings

From time to time we may be a defendant and/or plaintiff in various other legal proceedings arising in the normal course of our business. We are currently not a party to any material legal proceedings or government actions, including any bankruptcy, receivership, or similar proceedings. In addition, we are not aware of any known litigation or liabilities involving the operators of our properties that could affect our operations. Furthermore, as of the date of this Annual Report, our management is not aware of any proceedings to which any of our directors, officers, or affiliates, or any associate of any such director, officer, affiliate, or security holder is a party adverse to our company or has a material interest adverse to us.

ITEM 4.

MINE SAFETY DISCLOSURE

Not applicable.

Table of Contents

PART II

ITEM 5.

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

“Bid” and ”Ask” prices for our common stock have been reported through on the Over-The-Counter Bulletin Board (the “OTCBB”) under the symbol “BIAD.OB” and OTC Markets under the symbol “BIAD.QB since May 18, 2011 and under the symbol FXFL. OB from June 2007 through May 17, 2011. Prior to June 2007 our common stock was not quoted.

OTC Bulletin Board securities are not listed or traded on the floor of an organized national or regional stock exchange. Instead, OTC Bulletin Board securities transactions are conducted through a telephone and computer network connecting dealers in stocks. OTC Bulletin Board issuers are traditionally smaller companies that do not meet the financial and other listing requirements of a regional or national stock exchange.

The following table sets forth, for the fiscal quarters indicated, the high and low closing bid prices per share of our common stock as reported on the OTCBB, by the National Association of Securities Dealers Composite Feed or other qualified interdealer quotation medium. Such quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not represent actual transactions.

Quarter Ended	High Bid		Low Bid

December 31, 2015	$	0.13	$	0.07
September 30, 2015	$	0.13	$	0.09
June 30, 2015	$	0.20	$	0.10
March 31, 2015	$	0.29	$	0.09
December 31, 2014	$	0.13	$	0.04
September 30, 2014	$	0.15	$	0.06
June 30, 2014	$	0.15	$	0.12
March 31, 2014	$	0.16	$	0.10

As of December 31, 2015, we had 121 shareholders of record for our common stock.

Dividends

We have never declared any cash dividends with respect to our common stock. Future payment of dividends is within the discretion of our Board of Directors and will depend on our earnings, capital requirements, financial condition and other relevant factors. Although there are no material restrictions limiting, or that are likely to limit, our ability to pay dividends on our common stock, we presently intend to retain future earnings, if any, for use in our business and have no present intention to pay cash dividends on our common stock.

Recent Sales of Unregistered Securities

We sold no unregistered securities during the quarter ended December 31, 2015.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

None.

Equity Compensation Plan Information

The Company does not have any employee stock option or stock purchase plans at December 31, 2015.

During the period from March 10, 2006 (date of inception) through December 31, 2015, the following stock-based compensation was issued. On December 18, 2006, Mr. Thomas Barr received 412,038 shares, on May 22, 2007, Mr. Thomas Barr received 137,344 shares and on May 13, 2008, Mr. Paul Gothard received 65,000 shares. These shares were fair valued based on the fair value of each respective private placement.

Table of Contents

There were 10,100,000 warrants granted to members of our management and a key consultant during the fourth quarter of 2009. Of these, 5,200,000 of the warrants (the “Time Warrants”) vested as follows:

●	25% upon issuance;

●	25% on December 31, 2009;

●	25% on December 31, 2010; and

●	25% on December 31, 2011.

The vesting of 2,450,000 of the remaining 4,900,000 warrants was subject to our achieving an average closing price for our common stock of at least $0.45 per share over a period of twenty consecutive trading days on or prior to October 21, 2012 and the vesting of the remaining 2,450,000 warrants was subject to our achieving an average closing price for our common stock of at least $1.00 per share over a period of twenty consecutive trading days on or prior to October 21, 2012. The 4,900,000 warrants subject to our achieving average minimum closing prices for our common stock are hereinafter referred to as the “Price Warrants”. These pricing requirements were not met as of October 21, 2012 and the Price Warrants were terminated.

There were no other employee stock options granted to employees and directors during the period from March 10, 2006 (date of inception) through December 31, 2015.

ITEM 6.

SELECTED FINANCIAL DATA

Not applicable.

ITEM 7.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our audited consolidated financial statements and the accompanying notes included elsewhere in this Annual Report on Form 10-K.

The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of various factors, including those discussed in “Risk Factors” and elsewhere in this annual report.

Results of Operations

Net Loss

We incurred net losses in the amounts of $830,973 and $1,131,130 for the years ended December 31, 2015 and 2014, respectively. The net loss for the year ended 2014 was primarily due to additional developmental expenditure and a reduction in grant income. We have not yet generated any revenues since inception that can support our operating expenses. The net loss for the year for the year ended 2015 was primarily due to expenses as per the table below (see ‘operating loss’) together with general administration and operating costs.

Revenues and other Income

We generated no revenues during the year ended December 31, 2015.

We recorded other income during the period ended December 31, 2015 amounting to $80,450 comprised primarily of tax credits received from the UK tax authorities under a local tax incentive scheme for which one of our UK majority owned subsidiaries was eligible to apply. The tax credits cash payment received amounted to $77,674 for Bio-AMD, $942 relates to interest income and $1,834 other income for WL.

We recorded other income during the period ended December 31, 2014 amounting to $64,533 comprised primarily of tax credits received from the UK tax authorities under a local tax incentive scheme for which both of our UK majority owned subsidiaries were eligible to apply. The tax credits cash payments received amounted to $59,154 for Bio-AMD, $3,402 relates to interest income and $1,977 other income for WL.

Table of Contents

Operating loss

The main components of the recorded operating loss during the fiscal years ended December 31, 2015 and 2014 were as follows:

		Years ended December 31,
	Note	2015		2014
Consulting expenses	1	$	435,202	$	650,533
Payroll and administrative expenses	2	$	-	$	221,378
Legal fees	3	$	10,526	$	19,783
Professional fees	4	$	92,360	$	127,359
Rent, office related, telecoms and miscellaneous	5	$	94,083	$	99,879
Stock based consulting expense	6	$	238,000	$	-

(1)

Consulting expenses decreased by $215,331 to $435,202 for the year ended December 31, 2015, compared to $650,533 for the year ended December 31, 2014. Consulting expenses includes consultants engaged with the management and administration of the Company utilized in the course of our operations and those of our subsidiaries. The decrease was primarily due to certain consulting costs initially capitalized as deferred costs and which are directly associated with the performance of services for which revenue has been previously deferred. These costs will be recognized as a component of cost of revenue when the associated revenue is recognized. There were also reductions in the fees paid to consultants within both WL and Bio-AMD Inc. We are currently reviewing all Bio-AMD Inc. overhead expenditures to ensure that this is aligned to our financial circumstances.

(2)

Payroll and administrative expenses decreased by $221,378 from $221,378 for the year ended December 31, 2014 to $0 for the year ended December 31, 2015. The decrease was due to certain payroll and administrative costs initially capitalized as deferred costs and which are directly associated with the performance of services for which revenue has been previously deferred. These costs will be recognized as a component of cost of revenue when the associated revenue is recognized.

(3)	Legal fees decreased by $9,257 to $10,526 for the year ended December 31, 2015 as compared to $19,783 for the year ended December 31, 2014. We continue to monitor all advisor related expenditures to ensure maximum value at minimal cost.

(4)

Professional fees, comprised primarily of audit and financial compliance related costs, decreased by $34,999 from $127,359 for the year ended December 31, 2014 to $92,360 for the year ended December 31, 2015. The reduction for the twelve month period was primarily due to a revision of ongoing audit and related fees as agreed with our auditor.

(5)	Rent, Office related, Telecoms and Travel expense was $94,083 for the year ended December 31, 2015 as compared to $99,879 for the year ended December 31, 2014. The decrease of $5,796 can be attributed to rental charges ceasing on some premises.

(6)

Stock based consulting expense was $238,000 for the twelve month period ended December 31, 2015 compared to $0 for the twelve month period ended December 31, 2014. On June 9, 2015 the company entered into a consulting agreement with a consultant to provide investor relations services to Bio-AMD Inc., over a period of six months. As payment for these services we issued 1,150,000 restricted shares of our common stock in line with the consulting agreement. On the date of issuance, these shares were valued at $184,000 and, in line with the terms of the agreement, this non-cash charge has been expensed in full as a one-time payment on signing. On February 6, 2015 we issued 300,000 restricted shares of our common stock as payment for services to be supplied by a consultant to provide investor relationship services over a twelve month period pursuant to an agreement dated February 4, 2015. The value of these shares issued amounted to $54,000 and have been accounted for as prepaid expenses released over the contract term and was fully amortized in 2015.

Net loss Attributable to the non-controlling interests

Net loss attributable to the non-controlling interest amounted to $3,548 for the year ended December 31, 2015 compared to $137,424 for the year ended December 31, 2014. The net loss attributable to the non-controlling interests represented the 37% third party ownership of Bio-AMD’s and the 0.19% third party ownership of WL's share of its net loss for the applicable period.

Table of Contents

Liquidity and Capital Resources

We expect that we will need additional capital to implement our business strategies. There is no assurance that we will be able to raise the amount of capital that we seek for acquisitions or for future growth plans. Even if financing is available, it may not be on terms that are acceptable to us. In addition, we do not have any determined sources for any future funding. If we are unable to raise the necessary capital at the times we require such funding, we may have to materially change our business plan, including delaying implementation of aspects of our business plan or curtailing or abandoning our business plan. We represent a speculative investment and investors may lose all of their investment.

Since inception, we have been financed primarily by way of four separate private placements of our common stock and have raised approximately $18.98 million in total funds, net of legal and other fees totaling approximately $1.96 million. We raised $0.01 million for shares issued for founders in 2006; approximately $1.64 million on December 29, 2006; approximately $13.4 million on May 29, 2007; and $3.9 million on July 31, 2007.

At December 31, 2015, cash was $437,400 and we had other current assets of $670,757 which consisted of value added tax and other receivables, prepaid expenses and deferred charges; at the same time we had current liabilities of $1,053,105, which consisted of deferred revenue, accounts payable, accrued expenses, and taxation and social security. We attribute our net loss from operations to having no revenues to sustain our operating costs. At December 31, 2014, cash was $717,144 and we had other current assets of $33,619, which consisted of value added tax and other receivables and prepaid expenses and current liabilities of $50,310, which consisted of accounts payable, accrued expenses, taxation and social security.

Operations:

Net Cash Used in Operating Activities

Net cash used in operating activities of operations was $254,973 for the year ended December 31, 2015, as compared to net cash used of $1,173,247 for the year ended December 31, 2014. The decrease was primarily due to deferred expenditure being offset against the deferred revenue.

Net Cash Used in Investing Activities

During the years ended December 31, 2015 and 2014, we used $0 in investing.

Net Cash Used by Financing Activities

During the years ended December 31, 2015 and 2014, we used $0 in financing activities.

General

We intend to commit capital expenditures for any future projects requiring us to raise additional capital as and when adequate capital or new lines of finance are made available to us. There is no assurance that we will be able to obtain any financing or enter into any form of credit arrangement. Although we may be offered such financing, the terms may not be acceptable to us. If we are not able to secure financing or it is offered on unacceptable terms, then our business plan may have to be modified or curtailed or certain aspects terminated. There is no assurance that even with financing we will be able to achieve our goals.

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, our ability to continue as a going concern will be dependent upon our ability to generate sufficient cash flow from our planned operations to meet our obligations on a timely basis, to obtain additional financing, and ultimately attain profitability. The report of our independent accountants on our December 31, 2015 consolidated financial statements included an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern due to recurring losses. Our ability to continue as a going concern will be determined by our ability to obtain additional funding or generate sufficient revenue to cover our operating expenses. We currently have no sources of financing available and we do not expect to earn any revenues in the near term. Our consolidated financial statements do not include any adjustments that might result from the outcome of our inability to continue as a going concern.

Table of Contents

Critical Accounting Policies and Estimates

Use of estimates

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Going Concern

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, our ability to continue as a going concern will be dependent upon our ability to generate sufficient cash flow from our planned operations to meet our obligations on a timely basis, to obtain additional financing, and ultimately attain profitability. Also our ability to continue as a going concern will be determined by our ability to obtain additional funding or commence our planned business to generate sufficient revenue to cover our operating expenses. We currently have no sources of financing available and we do not expect to earn any revenues in the near term. Additionally, the Company has negative cash flows from operations for the year ended December 31, 2015 of $254,973 and has an accumulated deficit of $41,331,858 at December 31, 2015. These factors raise substantial doubt about our ability to continue as a going concern.

There can be no assurance that any additional financings will be available to the Company on satisfactory terms and conditions, if at all. In the event we are unable to continue as a going concern, we may elect or be required to seek protection from our creditors by filing a voluntary petition in bankruptcy or may be subject to an involuntary petition in bankruptcy. To date, management has not considered this alternative, nor does management view it as a likely occurrence.

The accompanying consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

Principles of consolidation

The consolidated financial statements include the accounts of Bio-AMD, Inc., WOCU Limited (a 99.81% owned subsidiary as of December 31, 2015) and Bio-AMD Holdings Limited (a 63% owned subsidiary as of December 31, 2015). All significant intercompany transactions and balances have been eliminated in consolidation.

The 0.19% third party ownership of WL and 37% third party ownership of Bio-AMD Holdings at December 31, 2015 and 2014 is recorded as non-controlling interests in the consolidated financial statements.

Foreign currency translation

The Company’s reporting and functional currency is US Dollars. The accounts of the Company’s 99.81% owned subsidiary, WL, and its 63% owned subsidiary, Bio-AMD Holdings, are maintained using the local currency (British Pounds) as the functional currency. All assets and liabilities are translated into U.S. Dollars at balance sheet date, shareholders’ equity is translated at historical rates and revenue and expense accounts are translated at the average exchange rate for the year or the reporting period. The translation adjustments are deferred as a separate component of stockholders’ equity, captioned as accumulated other comprehensive (loss) gain. Transaction gains and losses arising from exchange rate fluctuation on transactions denominated in a currency other than the functional currency are included in the consolidated statements of operations.

The relevant translation rates are as follows: For the year ended 2015 closing rate at 1.4802 US$: GBP, average rate at 1.5283 US$: GBP and for the year ended 2014 closing rate at 1.5532 US$: GBP, average rate at 1.6476 US$: GBP.

Revenue recognition

The Company recognizes revenue when the following criteria have been met: persuasive evidence of an arrangement exists, no significant Company obligations remain, collection of the related receivable is reasonably assured, and the fees are fixed or determinable. The Company acts as a principal in its revenue transactions as the Company is the primary obligor in the transactions.

Table of Contents

Deferred Revenue and Deferred Costs

The Company defers revenue on contracts which contain a performance commitment until such time as the services have been completed and no significant Company obligations remain.

The costs associated with contracts for which revenue is deferred, including personnel costs and incremental contract costs, are initially capitalized as deferred costs. Subsequently these costs are recognized as a component of cost of revenue when the associated revenue is recognized.

Non-controlling Interest

The 0.19% third party ownership of WL and 37% third party ownership of Bio-AMD at December 31, 2015 and 2014 are recorded as non-controlling interests in the consolidated financial statements. Details of changes in the non-controlling interests during the years ended December 31, 2015 and 2014 are reflected in the consolidated statement of stockholders’ equity.

Recently Issued Accounting Standards

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. This is part of FASB’s simplification initiative. The amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This ASU is effective for the Company in the first quarter of 2017. Early adoption is permitted. The Company does not expect the adoption of this amendment to have a material effect on its financial condition and results of operations.

In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU”) No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The amendments are to be applied on a retrospective basis, wherein the balance sheet of each individual period presented is adjusted to reflect the period-specific effects of applying the new guidance. We do not expect the adoption of ASU 2015-03 to have a material effect on our financial position, results of operations or cash flows.

In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). The ASU focuses on the consolidation evaluation for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. In addition to reducing the number of consolidation models from four to two, the new standard simplifies the FASB Accounting Standards Codification and improves current U.S. GAAP by placing more emphasis on risk of loss when determining a controlling financial interest, reducing the frequency of the application of related-party guidance when determining a controlling financial interest in a variable interest entity (“VIE”), and changing consolidation conclusions for companies in several industries that typically make use of limited partnerships or VIEs. The ASU will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not expect the adoption of ASU 2015-02 to have a material effect on our financial position, results of operations or cash flows.

In January 2015, the FASB issued ASU No. 2015-01, “Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” This ASU eliminates from U.S. GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. We do not expect the adoption of ASU 2015-01 to have a material effect on our financial position, results of operations or cash flows.

In November 2014, the FASB issued ASU No. 2014-17, “Business Combinations (Topic 805): Pushdown Accounting.” This ASU provides an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. An acquired entity may elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs. If pushdown accounting is applied to an individual change-in-control event, that election is irrevocable. ASU 2014-17 was effective on November 18, 2014. The adoption of ASU 2014-17 did not have any effect on our financial position, results of operations or cash flows.

Table of Contents

In November 2014, the FASB issued ASU 2014-16, “Derivatives and Hedging (Topic 815).” ASU 2014-16 addresses whether the host contract in a hybrid financial instrument issued in the form of a share should be accounted for as debt or equity. ASU 2014-16 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. We do not currently have issued, nor are we investors in, hybrid financial instruments. Accordingly, we do not expect the adoption of ASU 2014-16 to have any effect on our financial position, results of operations or cash flows.

In August 2014, the FASB issued ASU No. 2014-15, "Presentation of Financial Statements - Going Concern (Subtopic 205-40)". ASU 2014-15 provides guidance related to management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosure. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and for interim and annual periods thereafter. Early application is permitted. We do not expect the adoption of ASU 2014-15 to have a material effect on our financial position, results of operations or cash flows.

In June 2014, the FASB issued ASU No. 2014-12, “Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period.” This ASU requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. We do not expect the adoption of ASU 2014-12 to have a material effect on our financial position, results of operations or cash flows.

In June of 2014 the Financial Accounting Standards Board issued Accounting Standards Update ASU 2014-10, “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation” (“ASU 2014-10”). The amendments in ASU 2014-10 remove the definition of a development stage entity from the master glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.

The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.

The Company has elected to adopt the provisions of ASU 2014-10 for the fiscal period ending June 30, 2014. The adoption of ASU 2014-10 did not have a significant impact on our results of operations, financial condition or cash flow.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). ASU 2014-09 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. We are still evaluating the effect of the adoption of ASU 2014-09. On April 1, 2015, the FASB voted to propose to defer the effective date of the new revenue recognition standard by one year. In August 2015, the FASB issued ASU 2015-14, which defers the effective date of ASU 2014-09 by one year for all entities and permits early adoption on a limited basis. ASU 2014-09 will be effective for the Company in the first quarter of 2018, and early adoption permitted in the first quarter of 2017. The Company does not believe the adoption of this ASU will have a material impact on its consolidated financial statements.

In April 2014, the FASB issued ASU No. 2014-08, "Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360) and Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity." ASU 2014-08 amends the definition for what types of asset disposals are to be considered discontinued operations, as well as amending the required disclosures for discontinued operations and assets held for sale. ASU 2014-08 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2014. The adoption of ASU 2014-08 did not have any effect on our financial position, results of operations or cash flows.

Recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Off Balance Sheet Arrangements

None.

Table of Contents

Contractual Obligations

None.

Inflation

The effect of inflation on the Company's operating results was not significant.

ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable

ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Our consolidated financial statements are included beginning immediately following the signature page to this report. See Item 15 for a list of the consolidated financial statements included herein.

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding required disclosure. During the quarter ended December 31, 2015 we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13(a)-15(e) and 15d-15(e) under the 1934 Act. Based on this evaluation, management concluded that, as of December 31, 2015, our disclosure controls and procedures were effective.

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and dispositions of assets; (ii) provide reasonable assurances that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and the directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on our consolidated financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2015 based on the framework established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that assessment, management concluded that, as of December 31, 2015, our internal control over financial reporting was effective based on the criteria established in Internal Control—Integrated Framework.

This annual report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s independent registered public accounting firm pursuant to the rules of the SEC that permit smaller reporting companies to provide only the management’s report in this annual report on Form 10-K.

Table of Contents

Limitations on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer (principal financial officer), does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Our control systems are designed to provide such reasonable assurance of achieving their objectives. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Controls

During the fiscal quarter ended December 31, 2015, there have been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.

ITEM 9B.

OTHER INFORMATION

Not applicable.

Table of Contents

PART III

ITEM 10.

DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

Executive Officers, Directors and Key Employees

Directors serve until the next annual meeting of the stockholders; until their successors are elected or appointed and qualified, or until their prior resignation or removal. Officers serve for such terms as determined by our board of directors. Each officer holds office until such officer’s successor is elected or appointed and qualified or until such officer’s earlier resignation or removal. No family relationships exist between any of our present directors and officers. The following table sets forth certain information as of December 31, 2015, with respect to our directors and executive officers.

Name	Positions Held	Age	Date of Election or Appointment as Director

Thomas Barr	Chief Executive Officer and Director	56	December 2006
Robert Galvin	Chief Financial Officer, Treasurer, and Director	47	June 2009
David Miller	President, Secretary and Director	56	December 2008

Certain biographical information of our directors and officers is set forth below.

Thomas Barr: Mr. Barr has served as our chief executive officer since December 2008 and as a director of ours since December 2006. He has served as a director of WL since May 2009. He has expertise in corporate management, corporate governance and SEC reporting matters. He has been actively involved in the development of our corporate strategies including those involving our WL and Bio-AMD subsidiaries. He served as our Vice President of Alternative Fuels Operations from December 2006 until December 2008. From December 21, 2010 through the present, Mr. Barr has served as a director of Imperial Resources, Inc., a US public company engaged in oil and gas exploration and development. From January 2005 to April 2007, Mr. Barr acted as a consultant to small and medium sized private and public enterprises regarding prospective funding, investor and public relations strategy, collateral creation, website development and public market quotation. From December 2001 to December 2004, Mr. Barr served as a consultant to EasyScreen PLC, a fully listed London Stock Exchange company, at which Mr. Barr’s main duties were to draft and implement corporate statements. While serving as a consultant to EasyScreen PLC, Mr. Barr was an integral part of the team involved in several private placement funding rounds prior to the company’s acquisition. From January 1996 to November 2001 Mr. Barr was a private analyst and investor in publicly quoted stocks. From 1981 to 1996, Mr. Barr worked in the North Sea as a professional saturation diver involved in oil and gas field sub-sea construction. Mr. Barr obtained a BSc from Stirling University, Scotland, in 1981. Mr. Barr is a citizen of the United Kingdom. We took into account of his prior experience in operating public and private enterprises in corporate management, development of corporate strategies, private placement funding and SEC reporting matters and believe Mr. Barr’s past experience in these fields gives him the qualifications and skill to serve as our Chief Executive Officer and Director.

Robert Galvin: Mr. Galvin has served as our chief financial officer and treasurer since December 2008 and as a director of ours since June 2009. He also served as our secretary from December 2008 to June 2010. He has expertise in corporate finance and accounting, mergers and acquisitions, divestitures, and capital raising. He is a founding partner in the ARM Partnership, a corporate and financial advisory firm that specializes in small cap, venture backed fast growth businesses. He is also a co-founder, director and shareholder of Bio-AMD. He has served as a director of WL since July 7, 2010 and is also a shareholder of WL. From February 1996 to March 2002, he was a Director at Andersen Corporate Finance, prior to which Mr. Galvin worked in the commercial banking division of Barclays Plc. He has a first class honors degree BA (hons), and is an Associate of the Chartered Institute of Bankers. Mr. Galvin is a citizen of the United Kingdom. We took into account of his prior experience in corporate finance and accounting, mergers and acquisitions, divestitures, and capital funding and believe Mr. Galvin’s past experience in these fields gives him the qualifications and skill to serve as our Chief Financial Officer and Director.

David Miller: Mr. Miller has served as our president since June 2009, as our secretary since June 2010 and as a director of ours since December 2008. He has served as a director of WL from May 2009 until July 7, 2010. He has expertise in corporate management, development of business plans and strategies, sales and human resources matters. He has had an active role in the development of our WL business. He has been providing consultancy services to a venture capital provider since January 2009. From January 2006 through December 2008 he was the Sales Development Director for DX Group Ltd., which is a provider of specialized business mail and delivery services. From September 1999 through September 2005, Mr. Miller was the Sales and Marketing Director for MailSource UK Ltd. From 1978 through 1999, Mr. Miller was employed by Barclays Bank PLC, where his positions included Head of Regional Sales, South East Region, and Regional Sales Manager, Thames Valley Region.. Mr. Miller is a citizen of the United Kingdom. We took into account of his prior experience in corporate management, development of business plans and strategies, sales and human resources matters and believe Mr. Miller’s past experience in these fields gives him the qualifications and skill to serve as our President and Director.

Table of Contents

Employment Agreements

The Company has no direct employees as of December 31, 2015. All of the Company’s executive officers are engaged through consulting or supply of services agreements as set forth herein.

Effective July 1, 2009, we entered into a 12 month Supply of Services Agreement with Thomas Barr (the “Services Agreement”). Under the Services Agreement Mr. Barr serves as our Chief Executive Officer. Under the Services Agreement, Mr. Barr devotes a maximum average of up to five days per week to the performance of the services reasonably required by his positions. In the event we require the services of Mr. Barr for more than five days per week, we may, at our discretion, pay Mr. Barr for the additional days worked (the “Additional Time Payments”). The Services Agreement is subject to automatic extensions for additional 12 month periods, subject to an over-riding three month notice period for termination by either party. We pay Mr. Barr a base monthly fee under the Services Agreement of £7,916 (approximately $12,000) and reimburse Mr. Barr for his reasonable business expenses incurred in the performance of his duties. The base monthly fee includes an amount of £975 (approximately $1,500) for Board related duties. The Services Agreement also provides for the potential payment of additional compensation to Mr. Barr in the form of warrants, bonuses and incentive fees as determined by us. Notwithstanding the termination provisions above, we may terminate the Agreement for “Cause” effective upon the giving of written notice. If we terminate the Agreement without “Cause” we must pay Mr. Barr, in addition to all fees, unreimbursed expenses and Additional Time Payments due him at the termination date, the base monthly fees due to him through the expiration date in effect immediately prior to such termination. The Services Agreement contains standard confidentiality provisions. The Services Agreement also contains a non-compete provision which prohibits Mr. Barr, without our written consent, during the term of the Services Agreement and for a period of one year thereafter, from owning a material interest in, managing, operating, joining, controlling, lending money or rendering financial or other assistance to or participating in or being connected with, as an employee, contractor, stockholder, consultant or otherwise, any person or entity that competes with us in owning, operating or managing an oilseed crush or biodiesel plant located in England or Wales, or any other business actively being pursued by us or developed by us during the term of the Services Agreement.

Effective July 1, 2009 we entered into a 12 month Supply of Services Agreement (the “ARM Services Agreement”) with The ARM Partnership (“ARM”), a partnership in which Robert Galvin, our Chief Financial Officer and Treasurer is a partner. The term of the ARM Services Agreement has been extended until July 1, 2016. Thereunder, we receive the services of Mr. Galvin for an average of not more than 1.5 days per week. Mr. Galvin’s responsibilities under the ARM Services Agreement include oversight of our finance and internal control functions, review of our SEC filings, advising us on SEC regulatory matters, support with capital raisings and mergers and acquisitions and equivalent services. The ARM Services Agreement may be terminated by us for “Cause” or by us or ARM without “Cause”. Termination without “Cause” requires a minimum of 90 days prior written notice. Under the ARM Services Agreement, we pay the ARM a base monthly fee of £4,200 (approximately $6,400). The base monthly fee includes an amount of £975 (approximately $1,500) for Board related duties. In the event we require the services of Mr. Galvin for an average of more than 1.5 days per week, we may, at our discretion, pay ARM for the additional days worked (the “Additional Time Payments”). The ARM Services Agreement renews automatically for additional 12 month periods unless either party gives written notice to the other at least 6 months prior to the existing expiration date. The ARM Services Agreement provides for expense reimbursement and the potential payment of additional compensation in the form of warrants, bonuses, and incentive fees as determined by us. If we terminate the ARM Services Agreement without “Cause” we must pay ARM, in addition to all fees and unreimbursed expenses and Additional Time Payments due to ARM on the termination date, the base monthly fees due to ARM through the expiration date in effect immediately prior to such termination. The ARM Services Agreement contains standard confidentiality provisions. The ARM Services Agreement also contains a non-compete provision which prohibits ARM, without our written consent, during the term of the ARM Services Agreement and for a period of one year thereafter, from owning a material interest in, managing, operating, joining, controlling, lending money or rendering financial or other assistance to or participating in or being connected with, as an employee, contractor, stockholder, consultant or otherwise, any person or entity that competes with us in owning, operating or managing an oilseed crush or biodiesel plant located in England or Wales, or any other business actively being pursued by us or developed by us during the term of the ARM Services Agreement.

Effective July 1, 2009 we entered into a 12 month Supply of Services Agreement (the "Services Agreement") with David Miller under which Mr. Miller serves as our President and Secretary and provides us with his services, in all capacities, for an average of up to 3 days per week. We pay Mr. Miller a base monthly fee under the Services Agreement of £5,141 (approximately $7,800) per month. The base monthly fee includes an amount of £975 (approximately $1,500) for Board related duties. In the event that the performance of his duties under the Services Agreement require Mr. Miller to devote more than an average of 3 days per week to such performance, our board of directors may, in its sole discretion, pay Mr. Miller additional fees (the “Additional Time Payments”). The Services Agreement is subject to automatic extensions for additional 12 month periods, subject to an over-riding three month notice period for termination by either party Prior to the expiration date then in effect, we may terminate the Services Agreement upon 90 days prior written notice and Mr. Miller may terminate the Services Agreement upon 30 days prior written notice. The Services Agreement provides for expense reimbursement and the potential payment of additional compensation in the form of warrants, bonuses, and incentive fees as determined by us. Notwithstanding the termination provisions above, we may terminate the Services Agreement for "Cause" effective upon the giving of written notice. If we terminate the Services Agreement without "Cause" we must pay Mr. Miller, in addition to all fees and unreimbursed expenses and Additional Time Payments due to him on the termination date, the base monthly fees due to him through the expiration date in effect immediately prior to such termination. The Agreement contains standard confidentiality provisions. The Agreement also contains a non-compete provision which prohibits Mr. Miller, without our written consent, during the term of the Agreement and for a period of one year thereafter, from owning a material interest in, managing, operating, joining, controlling, lending money or rendering financial or other assistance to or participating in or being connected with, as an employee, contractor, stockholder, consultant or otherwise, any person or entity that competes with us in owning, operating or managing an oilseed crush or biodiesel plant located in England or Wales, or any other business actively being pursued by us or developed by us during the term of the Services Agreement.

Table of Contents

Term of Office

Our directors are appointed for a period of one year or until such time as their replacements have been elected by our shareholders. The officers of the Company are appointed by our board of directors and hold office until their resignation or removal.

Board Committees

We do not have a standing audit committee, an audit committee financial expert, or any committee or person performing a similar function. We do not have any board committees including a nominating, compensation, or executive committee. We currently have no operating revenues. Presently, we have no independent directors. Management does not believe that it is necessary at this time to retain independent directors to sit on an audit committee or any other committee. If we are able to grow our business and increase our operations in the future, then we will likely seek out and retain independent directors and form audit, compensation, and other applicable committees. Further, we do not have a policy with regard to the consideration of any director candidates recommended by security holders. Our three directors perform all functions that would otherwise be performed by committees.

Board of Directors and Board Compensation

All of our directors also serve as executive officers. We pay our directors a set monthly fee for attending board meetings of approximately $1,500. Our directors also receive compensation in their executive officer capacities.

Corporate Governance

Leadership Structure

Our Board has 3 members as follows: Mr. Thomas Barr, Mr. Robert Galvin and Mr. David Miller. We have not designated a Chairman and each of our directors assumes equal leadership roles.

Mr. Barr has served as chief executive officer since December 2008 and as a director of ours since December 2006. Mr. Barr serves on a full time basis.

Mr. Galvin has served as chief financial officer and treasurer since December 2008 and as a director since June 2009. He also served as our secretary from December 2008 until June 2010. Mr. Galvin serves on a part time basis.

Mr. Miller has served as president since June 2009, secretary since June 2010 and as a director since December 2008. Mr. Miller serves on a part time basis.

We are a small Company. Our three directors also serve as our executive officers. Our board members have complementary skills, enabling us to operate in a cost and time effective manner, closely managing our assets. Our Board regularly reviews this structure for optimum fit as our plans progress. We believe that our present management structure is appropriate for a company of our size and state of development.

Our board is actively involved in our risk oversight function and collectively undertakes risk oversight as part of its monthly management meetings. This review of our risk tolerances includes, but is not limited to, financial, legal and operational risks and other risks concerning our reputation and ethical standards.

Given our size, we do not have a Nominating Committee or a diversity policy. Our entire board monitors and assesses the need for and qualifications of additional directors. We may adopt a diversity policy in the future in connection with our anticipated growth.

Compliance with Section 16(a) of the Exchange Act

Section 16(a) of the Exchange Act requires our directors, officers and persons who own more than 10% of a registered class of our equity securities to file reports of ownership and changes in ownership with the Securities and Exchange Commission. Directors, officers and greater than 10% stockholders are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. Based solely upon our review of the copies of such forms that we received with respect to the fiscal year ended December 31, 2015, we believe that each person who at any time during the fiscal year was a director, officer or beneficial owner of more than 10% of our Common Stock satisfied their Section 16(a) filing requirements.

Table of Contents

Code of Ethics

On December 13, 2007 we adopted a Code of Ethics that applies to our executive officers. A copy of our Code of Ethics will be provided to any person requesting same without charge. To request a copy of our Code of Ethics, please make written request to our President c/o Bio-AMD, Inc. at 3rd Floor, 14 South Molton Street, London, W1K 5QP, United Kingdom.

ITEM 11.

EXECUTIVE COMPENSATION

The following table sets forth information concerning the total compensation paid or accrued by us during the two fiscal years ended December 31, 2015 and 2014 to (i) all individuals that served as our principal executive officer or acted in a similar capacity for us at any time during the two fiscal years ended December 31, 2015 and 2014; (ii) all individuals that served as our principal financial officer or acted in a similar capacity for us at any time during the two fiscal years ended December 31, 2015 and 2014; and (iii) all individuals that served as executive officers of ours at any time during the two fiscal years ended December 31, 2015 and 2014 that received annual compensation during the two fiscal years ended December 31, 2015 and 2014 in excess of $100,000.

Summary Compensation Table

Name and Principal Position	Year	Salary ($)		Bonus ($)		Stock Awards ($)		Option / Warrant Awards ($)		Non- Equity Incentive Plan Compensation ($)		Non- qualified Deferred Compensation Earnings ($)		All Other Compensation ($)		Total ($)

Thomas Barr – Chief Executive Officer (1)	2015 2014		145,176 156,509		- -		- -		- -		- -		- -		- -		145,176 156,509

Robert Galvin – Chief Financial Officer (1)	2015 2014		193,177 189,804		- -		- -		- -		- -		- -		- -		193,177 189,804

David Miller – President (1)	2015 2014		94,284 101,644		- -		- -		- -		- -		- -		- -		94,284 101,644

Except for our October 22, 2009 issuance of an aggregate of 10,100,000 warrants to members of our management and a key consultant (See Item 5. Market for Registrant’s Common Equity Related Shareholder Matters and Issuer Purchases of Equity Securities – Recent Sales of Unregistered Securities), we have not issued any stock options or warrants or maintained any stock option or other equity incentive plans since our inception. We have no plans in place and have never maintained any plans that provide for the payment of retirement benefits or benefits that will be paid primarily following retirement including, but not limited to, tax qualified deferred benefit plans, supplemental executive retirement plans, tax-qualified deferred contribution plans and nonqualified deferred contribution plans. Similarly, we have no contracts, agreements, plans or arrangements, whether written or unwritten, that provide for payments to the named executive officers or any other persons following, or in connection with the resignation, retirement or other termination of a named executive officer, or a change in control of us or a change in a named executive officer’s responsibilities following a change in control.

(1)	Since May 2009, the Directors compensation for the year includes a monthly fee of approximately $1,500 in respect of Board of Directors’ services.

Table of Contents

Outstanding Equity Awards at Fiscal Year-End

The following table sets forth information with respect to the warrants issued by us on October 22, 2009 to members of our management and outstanding at December 31, 2015:

Warrants

Stock Awards

Name

Number of Securities Underlying Unexercised Warrants

(#) Exercisable

Number of Securities Underlying Unexercised Warrants

(#) Unexercisable

Number of Securities Underlying Unexercised Unearned Warrants

(#)

Warrant Exercise Price (#)

Warrant Expiration Date

Number of Shares or Units of Stock That Have Not Vested

(#)

Market Value of Shares or Units of Stock That Have Not

Vested

($)

Number of Unearned Shares Units or Other Rights That Have Not Vested (#)

Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested

($)

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

Thomas Barr – CEO

2,900,000

(1)

0.07

October 21, 2016

N/A

Robert Galvin – CFO

1,000,000

(2)

0.07

October 21, 2016

N/A

David Miller – President

1,000,000

(3)

0.07

October 21, 2016

N/A

(1)	2,900,000 Price Warrants lapsed and terminated as the pricing requirements were not met as of October 21, 2012.

(2)	1,000,000 Price Warrants lapsed and terminated as the pricing requirements were not met as of October 21, 2012.

(3)	1,000,000 Price Warrants lapsed and terminated as the pricing requirements were not met as of October 21, 2012.

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table sets forth information with respect to the beneficial ownership of our common stock known by us as of March 21 2016 by:

Ÿ	each person or entity known by us to be the beneficial owner of more than 5% of our common stock;

Ÿ	each of our directors;

Ÿ	each of our executive officers; and

Ÿ	all of our directors and executive officers as a group.

Table of Contents

The percentages in the table have been calculated on the basis of treating as outstanding for a particular person, all shares of our common stock outstanding on such date and all shares of our common stock issuable to such holder in the event of exercise of outstanding options, warrants, rights or conversion privileges owned by such person at said date which are exercisable within 60 days of March 21, 2016. Unless otherwise indicated below each person’s address is c/o Bio-AMD, Inc., 3rd Floor, 14 South Molton Street, London, W1K 5QP, UK. Except as otherwise indicated, the persons listed below have sole voting and investment power with respect to all shares of our common stock owned by them, except to the extent such power may be shared with a spouse.

Name and Address of Beneficial Owner	Title of Class	Amount and Nature of Beneficial Ownership(1)			Percentage of Class(2)
Tresca International Inc. East 53rd Street Swiss bank building 2nd Floor Marbella Panama	Common Stock, $0.001 par value		2,929,998			6.37	%

Thomas Barr (director and officer)	Common Stock, $0.001 par value		3,749,382	(3)		7.67	%

Robert Galvin (director and officer)	Common Stock, $0.001 par value		1,000,000	(4)		2.12	%

David Miller (director and officer)	Common Stock, $0.001 par value		1,203,000	(5)		2.56	%

All officers and directors as a group (3 persons)	Common Stock, $0.001 par value		5,952,382	(3)(4)(5)		11.70	%

(1)

As used herein, the term beneficial ownership with respect to a security is defined by Rule 13d-3 under the Securities Exchange Act of 1934 as consisting of sole or shared voting power (including the power to vote or direct the vote) and/or sole or shared investment power (including the power to dispose or direct the disposition of) with respect to the security through any contract, arrangement, understanding, relationship or otherwise, including a right to acquire such power(s) within 60 days of March 1, 2015 Unless otherwise noted, beneficial ownership consists of sole ownership, voting and investment rights.

(2)	There were 45,975,966 shares of common stock issued and outstanding on March 21, 2016.

(3)	Includes 2,900,000 presently exercisable warrants.

(4)	Includes 1,000,000 presently exercisable warrants.

(5)	Includes 1,000,000 presently exercisable warrants.

Securities Authorized for Issuance Under Equity Compensation Plans

None

Other Employment Equity Awards

None

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

During the year ended December 31, 2015 and 2014, we paid an aggregate of $145,176 and $156,509, respectively to Thomas Barr for services provided to us by Mr. Barr in all capacities (See Item 10. Directors, Executive Officers, and Corporate Governance – Employment Agreements).

Table of Contents

During the year ended December 31, 2015 and 2014, we paid an aggregate of $193,177 and $189,804, respectively to The ARM Partnership (“ARM”), a partnership in which Robert Galvin, our Chief Financial Officer and Treasurer is a partner, for services provided to us by Mr. Galvin in all capacities (See Item 10. Directors, Executive Officers, and Corporate Governance – Employment Agreements and Item 1, Business, Operations, WL Currency Risk Mitigating Business, WL Corporate Strategy and Business Model). Mr. Galvin owns 12.33% of the outstanding share capital of Bio-AMD (see Item 1. Business – Operations). In addition, during the year ended December 31, 2015 and 2014 the Company paid a total of $14,900 and $24,714, respectively for the use of ARM’s offices in central London located at 3rd Floor, 14 South Molton Street, London, UK. The Company had use of the office space for internal, board and third party meetings and document storage. The rental charge for use of the premises by the Company was set at £500 per month for Bio-AMD Inc. (approximately $760), this ceased on July 31, 2015 and £750 per month for Bio-AMD Holdings (approximately $1,150), reduced to £500 (approximately $760) for each of the months of August and September, 2015, and which ceased on September 30, 2015.

During the year ended December 31, 2015 and 2014, we paid an aggregate of $94,284 and $101,644, respectively to David Miller for services provided to us by Mr. Miller in all capacities (See Item 10. Directors, Executive Officers, and Corporate Governance – Employment Agreements).

Director Independence

None of our three present directors are “independent” as that term is defined by the National Association of Securities Dealers Automated Quotations (“NASDAQ”) as they also serve as executive officers.

ITEM 14.

PRINCIPAL ACCOUNTANT FEES AND SERVICES

Audit Fees

The aggregate fees billed to us by RBSM LLP, our principal accountant for professional services rendered during the fiscal years ended December 31, 2015 and 2014 are set forth in the table below:

Fee Category	Fiscal year ended December 31, 2015		Fiscal year ended December 31, 2014

Audit fees (1)	$	87,360	$	115,000
Audit-related fees (2)		-		-
Tax fees (3)		5,000		5,000
All other fees (4)		-		-
Total fees	$	92,360	$	120,000

(1)

Audit fees consist of fees incurred for professional services rendered for the audit of consolidated financial statements, for reviews of our interim consolidated financial statements included in our quarterly reports on Form 10-Q and for services that are normally provided in connection with statutory or regulatory filings or engagements.

(2)	Audit-related fees consist of fees billed for professional services that are reasonably related to the performance of the audit or review of our consolidated financial statements, but are not reported under “Audit fees.”

(3)	Tax fees consist of fees billed for professional services relating to tax compliance, tax planning, and tax advice.

(4)	All other fees consist of fees billed for all other services.

Audit Committee’s Pre-Approval Practice.

Prior to our engagement of our independent auditor, such engagement was approved by our board of directors. The services provided under this engagement may include audit services, audit-related services, tax services and other services. Pre-approval is generally provided for up to one year and any pre-approval is detailed as to the particular service or category of services and is generally subject to a specific budget. Pursuant our requirements, the independent auditors and management are required to report to our board of directors at least quarterly regarding the extent of services provided by the independent auditors in accordance with this pre-approval, and the fees for the services performed to date. Our board of directors may also pre-approve particular services on a case-by-case basis. All audit-related fees, tax fees and other fees incurred by us for the year ended December 31, 2015, were approved by our board of directors.

Table of Contents

PART IV

ITEM 15.

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Consolidated Financial Statements

See Index to Consolidated Financial Statements immediately following the signature page of this report.

Financial Statement Schedules

All consolidated financial statement schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or notes thereto.

Exhibits

In reviewing the agreements included as exhibits to this Form 10-K, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about the Company or the other parties to the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the parties to the applicable agreement and:

§	should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;

§	have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;

§	may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and

§	were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about the Company may be found elsewhere in this Form 10-K and the Company’s other public filings, which are available without charge through the SEC’s website at http://www.sec.gov.

Table of Contents

The following exhibits are included as part of this report:

Exhibit No.	SEC Report Reference No.	Description

2.1	2.1	Articles of Merger as filed with the Nevada Secretary of State on April 15, 2011 (12)

2.2	2.2	Agreement and Plan of Merger dated April 15, 2011 by and between Flex Fuels Energy, Inc. and Bio-AMD, Inc. (12)

3.1	3.1	Articles of Incorporation of Registrant dated March 10, 2006 (1)

3.2	3.2	By-laws of the Company (1)

3.3	3.1	Articles of Association of WDX Organisation Limited adopted on July 21, 2010 (2)

4.1	4.1	Form of October 22, 2009 Time Warrant (3)

4.2	4.2	Form of October 22, 2009 Price Warrant (3)

4.3	4.1	WDX Organisation Limited Subscription Agreement dated July 23, 2010 (2)

10.1	10.1	Asset Purchase Agreement dated March 27, 2006, entered into by and between James Laird and Registrant (4)

10.2	10.1	Acquisition Agreement dated December 29, 2006 entered into by and among Registrant, Flex Fuels Energy Limited, the stockholders of Flex Fuels Energy Limited and the individuals signatory thereto (4)

10.3	10.4	Subscription Agreement dated December 29, 2006 entered into by and among Registrant and the subscribers’ signatories thereto (5)

10.4	10.1	Stock Purchase Agreement dated May 21, 2009 between Registrant and Iestyn Morgan (6)

10.5	10.2	Stock Purchase Agreement dated May 21, 2009 between Registrant and Mark Paulson (6)

10.6	10.3	Stock Purchase Agreement dated May 21, 2009 between Registrant and Gillian Penton (6)

10.7	10.1	Stock Purchase Agreement dated October 9, 2009 between Registrant and JTC Trustees Limited as Trustee of the LOGO Investment Trust (7)

10.8	10.1	Supply of Services Agreement dated July 1, 2009 between Registrant and David Miller (8)

10.9	10.2	Supply of Services Agreement dated July 1, 2009 between Registrant and Thomas Barr (8)

10.10	10.3	Supply of Services Agreement dated July 1, 2009 between Registrant and The ARM Partnership (8)

10.11	10.1	Subscription and Shareholders’ Agreement, dated February 25, 2010 among Registrant, Bio AMD Holdings Limited (“Bio AMD”) and the Managers of Bio AMD (9)

Table of Contents

Exhibit No.	SEC Report Reference No.	Description

10.12	10.2	Service Agreement dated February 25, 2010 between Bio Alternative Medical Devices Limited and Dr. Nasr-Eddine Djennati (9)

10.13	10.3	Service Agreement dated February 25, 2010 between Bio Alternative Medical Devices Limited and Dr. Andrew Mitchell (9)

10.14	10.4	Consultancy Agreement dated February 25, 2010 between Bio Alternative Medical Devices Limited and The ARM Partnership (9)

10.15	10.20	Investment Agreement dated May 1 2009 between Registrant and WDX Organisation Ltd (10)

10.16	10.21	Loan Agreement dated May 1 2009 between Registrant and WDX Organisation Ltd (10)

10.17	10.17	Deed of Variation dated July 21, 2011 to WDX Loan Agreement dated May 1, 2009 (11)

10.18	10.18	Consultancy Agreement effective July 1, 2010 between WDX Organisation Ltd and The ARM Partnership (11)

14.1	14.1	Code of Ethics (5)

21	*	List of Subsidiaries

31.1	*	Rule 13(a)-14(a)/15(d)-14(a) Certification of Principal Executive Officer

31.2	*	Rule 13(a)-14(a)/15(d)-14(a) Certification of Principal Financial Officer

32.1	*	Rule 1350 Certification of Chief Executive Officer

32.2	*	Rule 1350 Certification of Chief Financial Officer

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

Table of Contents

(1)	Filed with the Securities and Exchange Commission on August 4, 2006, as an exhibit, numbered as indicated above, to the Registrant’s registration statement on the Registrant’s Registration Statement on Form SB-1 (file no. 333-136349), which exhibit is incorporated herein by reference.

(2)	Filed with the Securities and Exchange Commission on July 29, 2010, as an exhibit, numbered as indicated above, to the Registrant’s Current Report on Form 8-K dated July 23, 2010, which exhibit is incorporated herein by reference.

(3)	Filed with the Securities and Exchange Commission on November 19, 2009, as an exhibit, numbered as indicated above, to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, which exhibit is incorporated herein by reference.

(4)	Filed with the Securities and Exchange Commission on January 5, 2007, as an exhibit, numbered as indicated above, to the Registrant’s Current Report on Form 8-K dated December 29, 2006, which exhibit is incorporated herein by reference.

(5)	Filed with the Securities and Exchange Commission on April 17, 2007, as an exhibit, numbered as indicated above, to the Registrant’s Annual Report on Form 10-KSB for the year ended December 31, 2006, which exhibit is incorporated herein by reference.

(6)	Filed with the Securities and Exchange Commission on May 27, 2009, as an exhibit, numbered as indicated above, to the Registrant’s Current Report on Form 8-K dated May 21, 2009, which exhibit is incorporated herein by reference.

(7)	Filed with the Securities and Exchange Commission on October 13, 2009, as an exhibit, numbered as indicated above, to the Registrant’s Current Report on Form 8-K dated October 9, 2009, which exhibit is incorporated herein by reference.

(8)	Filed with the Securities and Exchange Commission on August 19, 2009, as an exhibit, numbered as indicated above, to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, which exhibit is incorporated herein by reference.

(9)	Field with the Securities and Exchange Commission on March 3, 2010, as an exhibit, numbered as indicated above, to the Registrant’s Current Report on Form 8-K dated February 25, 2010, which exhibit is incorporated herein by reference.

(10)	Filed with the Securities and Exchange Commission on March 22, 2010, as an exhibit, numbered as indicated above, to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2009, which exhibit is incorporated herein by reference.

(11)	Filed with the Securities and Exchange Commission on March 23 2011, as an exhibit, numbered as indicated above, to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2010, which exhibit is incorporated herein by reference.

(12)	Filed with the Securities and Exchange Commission on April 20, 2011, as an exhibit, numbered as indicated above, to the Registrant’s Current Report on Form 8-K dated April 15, 2011, which exhibit is incorporated herein by reference.

* Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIO-AMD, INC.

Dated: March 30, 2016	By:	/s/ Thomas Barr
		Thomas Barr, Chief Executive Officer and Director


Dated: March 30, 2016	By:	/s/ Robert Galvin
		Robert Galvin, Chief Financial and Accounting Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

/s/ Thomas Barr		March 30, 2016
Thomas Barr, Chief Executive Officer and Director

/s/ Robert Galvin		March 30, 2016
Robert Galvin, Chief Financial and Accounting Officer, Treasurer and Director

/s/ David Miller		March 30, 2016
David Miller, President, Secretary and Director

Table of Contents

FINANCIAL STATEMENTS

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

	Page

Report of Independent Registered Public Accounting Firm	F-1

Consolidated Balance Sheets as of December 31, 2015 and 2014	F-2

Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2015 and 2014	F-3

Consolidated Statements of Equity for the Years Ended December 31, 2015 and 2014	F-4

Consolidated Statements of Cash Flows for the Years Ended December 31, 2015 and 2014	F-5

Notes to Consolidated Financial Statements	F-6 to F-15

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of

Bio-AMD, Inc.

We have audited the accompanying consolidated balance sheets of Bio-AMD, Inc. and Subsidiaries (the “Company”) as of December 31, 2015 and 2014, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2015. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We have conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States of America). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Bio-AMD, Inc. and Subsidiaries as of December 31, 2015 and 2014, and the consolidated results of their operations and their cash flows for each of the two years in the period ended December 31, 2015 in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 1 to the accompanying consolidated financial statements, the Company has not commenced its planned principal operations, has suffered recurring losses since inception and is experiencing difficulty in generating sufficient cash flow to sustain its operations, which raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to this matter are described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ RBSM LLP

New York, New York

March 30, 2016

F-1

Table of Contents

Bio-AMD, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	December 31,			December 31,
	2015			2014

ASSETS
Current Assets:
Cash and cash equivalents	$	437,400		$	717,144
Prepaid expenses		12,251			9,556
Value added tax and other receivables		12,972			24,063
Deferred charges		645,534			-

Total Current Assets		1,108,157			750,763

Property and equipment, net		157			277

Security deposits and other assets		165,848			132,671

Total Assets	$	1,274,162		$	883,711

LIABILITIES AND EQUITY

Current Liabilities:
Accounts payable	$	62,149		$	30,320
Accrued expenses		23,239			10,010
Taxation and social security		17,316			9,980
Deferred revenue		950,402			-

Total Current Liabilities		1,053,106			50,310

Total Liabilities		1,053,106			50,310

Commitments and contingencies		-			-

Equity:
Bio-AMD, Inc. Stockholders' Equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2015 and 2014		-			-
Common stock, $0.001 par value, 500,000,000 shares authorized, 45,975,966 and 44,525,966 shares issued and outstanding at December 31, 2015 and 2014, respectively		45,976			44,526
Additional Paid-in Capital		42,589,759			42,329,451
Accumulated other comprehensive income - foreign currency translation adjustment		73,243			102,589
Accumulated deficit		(41,331,858	)		(40,504,433	)
Total Bio-AMD, Inc. Stockholders' Equity		1,377,120			1,972,133
Non-controlling interest		(1,156,064	)		(1,138,732	)
Total Equity		221,056			833,401

Total Liabilities and Equity	$	1,274,162		$	883,711

The accompanying notes are an integral part of these consolidated financial statements.

F-2

Table of Contents

Bio-AMD, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	For the years ended December 31,
	2015			2014

Revenue	$	-		$	-

Operating expenses:
Selling, general and administrative charges		911,423			1,195,662

Total operating expense		911,423			1,195,662

Operating loss		(911,423	)		(1,195,662	)

Other income:
Grant income		77,674			59,154
Interest and other income		2,776			5,378

Loss from operations, before provision for income taxes		(830,973	)		(1,131,130	)

Provision for income tax		-			-

Net loss		(830,973	)		(1,131,130	)

Net loss attributable to the non-controlling interest		(3,548	)		(137,424	)
Subsidiary preferred dividend attributable to the non-controlling interest		(23,758	)		(24,929	)

Net loss attributable to Bio-AMD, Inc. Common Shareholders	$	(803,667	)	$	(968,777	)

Net loss per common share attributable to Bio-AMD, Inc. common shareholders - basic	$	(0.02	)	$	(0.02	)
Net loss per common share attributable to Bio-AMD, Inc. common shareholders - diluted	$	(0.02	)	$	(0.02	)

Weighted average number of common shares outstanding - basic		45,445,418			44,525,966

Weighted average number of common shares outstanding - diluted		45,445,418			44,525,966

Comprehensive Loss:
Net loss	$	(830,973	)	$	(1,131,130	)
Other comprehensive loss, net of tax:
Foreign currency translation adjustment, net of tax		(19,372	)		(38,660	)
Total other comprehensive loss, net of tax		(850,345	)		(1,169,790	)
Comprehensive (income)/loss attributable to the non-controlling interest		(6,426	)		126,143
Comprehensive loss attributable to the Bio-AMD Inc. Common Shareholders	$	(856,771	)	$	(1,043,647	)

The accompanying notes are an integral part of these consolidated financial statements.

F-3

Table of Contents

Bio-AMD, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF EQUITY

										Accumulated
					Additional					Other
	Common Stock				Paid-in		Accumulated			Comprehensive			Noncontrolling			Total
	Shares		Amount		Capital		Deficit			Income			Interest			Equity
Balance at December 31, 2013		44,525,966	$	44,526	$	42,304,522	$	(39,510,727	)	$	152,530		$	(987,660	)	$	2,003,191

Comprehensive loss											(49,941	)		11,281			(38,660	)

Subsidiary preferred dividend						24,929								(24,929	)		-

Net loss								(993,706	)					(137,424	)		(1,131,130	)
Balance at December 31, 2014		44,525,966		44,526		42,329,451		(40,504,433	)		102,589			(1,138,732	)		833,401

Issuance of shares for prepaid services		300,000		300		53,700		-			-			-			54,000

Issuance of shares for services		1,150,000		1,150		182,850		-			-			-			184,000

Comprehensive loss		-		-		-		-			(29,346	)		9,974			(19,372	)

Subsidiary preferred dividend		-		-		23,758		-			-			(23,758	)		-

Net loss		-		-		-		(827,425	)		-			(3,548	)		(830,973	)
Balance at December 31, 2015		45,975,966	$	45,976	$	42,589,759	$	(41,331,858	)	$	73,243		$	(1,156,064	)	$	221,056

The accompanying notes are an integral part of these consolidated financial statements.

F-4

Table of Contents

Bio-AMD, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the years ended December 31,
	2015			2014
Cash flows from operating activities:
Net loss	$	(830,973	)	$	(1,131,130	)

Adjustments to reconcile net loss to net cash used in operating activities:
Stock based consulting fees		238,000			-
Depreciation		110			565
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(2,863	)		(1,215	)
Sales tax and other receivable		10,656			28,526
Deferred charges		(666,511	)		-
Security deposit and other assets		(40,693	)		(52,773	)
Accounts payable		47,958			(20,596	)
Taxation and social security payable		8,057			3,376
Deferred revenue		981,286			-
Total Adjustments		576,000			(42,117	)

Net cash used in operating activities		(254,973	)		(1,173,247	)

Cash flows from investing activities:		-			-

Cash flows from financing activities:		-			-

Effects of exchange rate changes on cash		(24,771	)		(31,504	)

Net decrease in cash and cash equivalents		(279,744	)		(1,204,751	)

Cash and cash equivalents, beginning of period		717,144			1,921,895

Cash and cash equivalents, end of period	$	437,400		$	717,144

Supplementary disclosure of cash flow information:
Cash paid during the period for:
Interest	$	-		$	-
Income tax	$	-		$	-

Supplemental schedule of non-cash investing and financing activities:	$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements.

F-5

Table of Contents

Bio-AMD, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, 2015 and 2014

Note 1 - Nature of Operations and Going Concern

Nature of Operations

Bio-AMD, Inc. (“Bio-AMD” the “Company”, “we”, “us”, “our”) (formerly Flex Fuels Energy, Inc. and Malibu Minerals, Inc.) was incorporated in the State of Nevada on March 10, 2006 to engage in the business of exploration and discovery of gold, minerals, mineral deposits and reserves.

On April 15, 2011, we entered into an Agreement and Plan of Merger (the "Merger Agreement") pursuant to which we merged with our newly formed, wholly owned subsidiary, Bio-AMD, Inc., a Nevada corporation ("Merger Sub" and such merger transaction, the "Merger"). Upon the consummation of the Merger, the separate existence of Merger Sub ceased and shareholders of the Company became shareholders of the surviving company named Bio-AMD, Inc. As permitted by Chapter 92A.180 of Nevada Revised Statutes, the sole purpose of the Merger was to effect a change of our name. Upon the filing of Articles of Merger (the "Articles of Merger") with the Secretary of State of Nevada on April 15, 2011 to effect the Merger, our Articles of Incorporation were deemed amended to reflect the change in our corporate name. We are quoted on OTC Markets and the OTC Bulletin Board under the symbol “BIAD”. We changed our name to “Bio-AMD, Inc.” to reflect a name which recognizes our core business area.

During the fourth quarter of our 2006 fiscal year, for the purpose of diversifying our business, acquiring capital, gaining greater access to the capital markets and with the assistance of newly acquired capital, we entered into an Agreement with Flex Fuels Energy Limited (“FFE Ltd”) and the stockholders of FFE Ltd and FFE Ltd became our wholly-owned subsidiary effective on May 29, 2007. FFE Ltd engaged in the development of the business of manufacturing and distributing Oil Seed Rape (“OSR”) products.

Effective September 5, 2009, after having carefully evaluated all options, we determined to abandon our proposed oil seed business as we no longer considered the business to be economically viable on either a go alone or partnered basis. The proposed project initiated by prior management involving the establishment of an oil seed crushing plant at Cardiff, Wales by our wholly owned subsidiary, FFE Ltd, was compromised by constant delays, sub-optional design and substantial legal costs. We were unable to raise the approximately $123,000,000 needed for maximum project efficiency, to locate a project partner, or to divest our interest in the project for value. Accordingly, we determined that our best course of action was to preserve value by winding down the oil seed operations of FFE Ltd. which we have done on an orderly basis.

FFE Ltd. was formally dissolved in February 2011; the final winding down accounting transactions took place in May 2011.

From our inception through the date of these consolidated financial statements, we have not generated any revenues and have incurred significant expenses. The Company intends to fund its development of the currency risk technology, diagnostic technology and on-going operations through equity and/or debt financing arrangements. However, there can be no assurance that these arrangements will be sufficient to fund its ongoing capital expenditures, working capital, and other cash requirements. Consequently, our operations are subject to all the risks and uncertainties inherent in the establishment of a new business enterprise.

WOCU Limited Acquisition

On May 1, 2009, we entered into an Investment Agreement (the “Investment Agreement”) with WDX Organisation Limited, a corporation incorporated under the laws of England and Wales, and the founding shareholders of WDX Organisation Limited (the “Founders”), the owners of all of the issued and outstanding shares of WDX Organisation Limited. On the same date, we entered into a related Loan Agreement (the “Loan Agreement”) and a related Option and Funding Agreement (the “Funding Agreement”) with WDX Organisation Ltd. The Investment Agreement, Loan Agreement and Funding Agreement are hereinafter collectively referred to as the “Agreements”. Pursuant to the Agreements we acquired 51% ownership of WDX Organisation Limited. WDX Organisation Limited changed its name to WOCU Limited (“WL”) effective January 29, 2013.

WL is the developer of a technology designed to mitigate currency risk. On August 14, 2009 we provided a further £150,000 (approximately $247,800) to WL by way of a loan and have exercised certain call options. On November 20, 2009 we loaned an additional £150,000 (approximately $249,840) to WL and increased our equity position in WL. Altogether, these transactions have resulted in a total loan of £450,000 (approximately $717,000) to WL and the ownership of 75.66% of WL by the Company, as at the fiscal year ended December 31, 2009. During fiscal year ended December 31, 2010, WL applied for an international patent over its algorithm and system of providing reference data for the global currency unit, and has been working to develop contracts with a variety of banks, currency exchange networks, data providers and derivative exchanges in an effort to commercialize its technology through licensing agreements.

F-6

Table of Contents

On March 8, 2010, we loaned an additional £150,000 (approximately $224,055) to WL and executed certain call options and further increased our equity position in WL. The loans were the result of our ongoing investment in WL as contemplated by our May 1, 2009 Investment Agreement with WL. Altogether, these transactions resulted in a total loan of £600,000 (approximately $904,000) to WL and the ownership of 93% of WL by the Company on March 8, 2010.

On July 23, 2010 we entered into a Subscription Agreement with WL and the founders of WL under which we purchased 500,000 preference shares of WL (the “Preference Shares”) at a price of one British Pound per share or an aggregate of £500,000 (approximately $750,000). The Preference Shares earn in priority to any other class of stock of WL, a cumulative dividend equal to 5% of the subscription price of such Preference Shares per annum. These Preference Shares carry a preference over all other classes of WL stock in the event of a sale, liquidation or listing of WL. Upon liquidation, sale or listing and after repayment of the outstanding loans made by us to WL, other liabilities of WL and related transaction costs, the holder of the Preference Shares is entitled to a payment equal to three times the subscription price (the “Preference Shares Payment”) paid for such Preference Shares. The Preference Shares are redeemable upon a sale, listing or winding down of WL.

The Subscription Agreement also provided for WL to allot up to an aggregate of 16,900 C Ordinary Shares of WL to employees, directors and consultants of WL to secure their continued service to WL and incentivize them in the performance thereof. An aggregate of 14,061 C Ordinary Shares were issued, for nominal consideration, to four persons on July 23, 2010. The issuance of the 14,061 C Ordinary Shares reduced our ownership in WL from 93% to 77.54%.

Effective June 30, 2011, WL agreed with all three of its employees to terminate existing employment agreements so as to reduce the monthly cash outflows. As a result of the termination of employment contracts and in accordance with the WL Articles of Association terminated employees gave up 9,243 C Ordinary Shares. This increased our ownership in WL to 87.13%.

During November 2011 we loaned an additional £50,000 to WL as a short-term unsecured intercompany loan. On July 12, 2012 it was agreed that this loan will be settled through the issuance to us of 5,000,000 ordinary shares, increasing our ownership in WL to 99.81%.

To date, there were no commercial agreements in place, and no revenues had been generated by WL.

Bio-AMD Holdings Limited Acquisition

On February 25, 2010, we entered into a Subscription and Shareholders Agreement with Bio-AMD Holdings Limited (“Bio-AMD Holdings”), a United Kingdom company, and the managers of Bio-AMD Holdings, under which we acquired a 63% interest in Bio-AMD Holdings for £865,000 (approximately $1,335,000) through the purchase of preferred shares. The preferred shares accrue dividends at the rate of 5% per year and provide for a preference in liquidation equal to £865,000, plus accrued unpaid dividends (the preference on a sale is £850,000, plus accrued and unpaid dividends). Bio-AMD Holdings is a development stage company, formed in February 2010, which, through its operating subsidiary, Bio Alternative Medical Devices Ltd. (“Bio-Medical”), principally operates in the Medical Point of Care (“PoC”) diagnostic space. Where context requires, reference to Bio-AMD Holdings also includes reference to Bio-Medical. Bio-AMD Holdings owns a portfolio of patent applications on technologies which it expects to enable it to develop highly accurate, low cost, hand held electronic diagnostic devices capable of reading third party assays. Since 2010 Bio-AMD Holdings has been developing its technology into three initial product types 1) a digital strip reader targeted initially into the “over the counter” pregnancy testing market, 2) a blood coagulation device and 3) early stage development work into a quantitative magnetic immunoassay detection system. In addition, Bio-AMD Holdings has worked on the development of various commercial relationships with manufacturers, bio-chemistry companies and sales distributions partners to enable commercialization of its products through licensing agreements. As at the date of this Annual Report, there were no commercial agreements in place, and no revenues had been generated by Bio-AMD Holdings.

Bio-AMD, Inc., WL, a majority-owned subsidiary, Bio-AMD Holdings, a majority-owned subsidiary, and FFE Ltd. (dissolved in 2011), are hereafter collectively referred to as “Bio-AMD”, “we”, “us”, “our” or, the “Company”.

F-7

Table of Contents

Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not commenced its planned principal operations. As shown in the accompanying consolidated financial statements, the Company has not generated any revenue and has incurred recurring losses through December 31, 2015. Additionally, the Company has recurring negative cash flows from operations and has an accumulated deficit of $41,331,858 at December 31, 2015. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company’s ability to continue its existence is dependent upon commencing its planned operations, management’s ability to develop and achieve profitable operations and/or upon obtaining additional financing to carry out its planned business. The Company intends to fund its development of the currency risk technology, diagnostic technology and on-going operations through equity and debt financing arrangements. We currently have no sources of financing available and we do not expect to earn any revenues in the near term. However, there can be no assurance that these arrangements will be sufficient to fund its ongoing capital expenditures, working capital, and other cash requirements. The outcome of these matters cannot be predicted at this time.

Note 2 - Summary of Significant Accounting Policies

Use of estimates

Principles of consolidation

Foreign currency translation

The Company’s reporting and functional currency is US Dollars. The accounts of the Company’s 99.81% owned subsidiary, WL, and its 63% owned subsidiary, Bio-AMD Holdings, are maintained using the local currency (Great British Pound) as the functional currency. All assets and liabilities are translated into U.S. Dollars at balance sheet date, shareholders’ equity is translated at historical rates and revenue and expense accounts are translated at the average exchange rate for the year or the reporting period. The translation adjustments are deferred as a separate component of stockholders’ equity, captioned as accumulated other comprehensive (loss) gain. Transaction gains and losses arising from exchange rate fluctuation on transactions denominated in a currency other than the functional currency are included in the consolidated statements of operations.

F-8

Table of Contents

Revenue recognition

Deferred Revenue and Deferred Costs

The Company defers revenue on contracts which contain a performance commitment until such time as the services have been completed and no significant Company obligations remain.

Non-controlling Interest

The 0.19% third party ownership of WL and 37% third party ownership of Bio-AMD Holdings at December 31, 2015 and 2014 are recorded as non-controlling interests in the consolidated financial statements. Details of changes in the non-controlling interests during the years ended December 31, 2015 and 2014 are reflected in the consolidated statement of equity.

Recently Issued Accounting Standards

F-9

Table of Contents

The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.

F-10

Table of Contents

Note 3 - Property and Equipment

Property and equipment consists of the following at December 31, 2015 and 2014:

	December 31,			December 31,
	2015			2014
Assets:
Office equipment and furniture	$	10,236		$	11,383
Accumulated depreciation and amortization		(10,079	)		(11,106	)
Carrying value	$	157		$	277

Depreciation expense was $110 and $565 for the years ended December 31, 2015 and 2014, respectively.

Note 4 - Related Party Transactions

During the years ended December 31, 2015 and 2014, we paid an aggregate of $193,177 and $189,804, respectively to The ARM Partnership (“ARM”) a partnership in which Robert Galvin, our Chief Financial Officer and Treasurer is a partner, for services provided to us by Mr. Galvin in all capacities. Mr. Galvin owns 12.33% of the outstanding share capital of Bio-AMD Holdings. In addition, the Company paid a total of £9,750 and £15,000 during the years ended December 31, 2015 and 2014, respectively, (approximately $14,900 and $24,700, respectively) for the use of ARM’s offices in central London located at 3rd Floor, 14 South Molton Street, London, UK. The Company has had use of the office space for internal, board and third party meetings and document storage. The rental charge for use of the premises by the Company was set at £500 per month for Bio-AMD Inc. (approximately $760), this ceased on July 31, 2015 and £750 per month for Bio-AMD Holdings (approximately $1,150), reduced to £500 (approximately $760) for each of the months of August and September, 2015, and which ceased on September 30, 2015.

During the year ended December 31, 2015 and 2014, we paid an aggregate of $145,176 and $156,509, respectively to Thomas Barr for services provided to us by Mr. Barr in all capacities.

During the year ended December 31, 2015 and 2014, we paid an aggregate of $94,284 and $101,644, respectively to David Miller for services provided to us by Mr. Miller in all capacities.

Note 5 - Commitments and Contingencies

Lease commitments

The Company has no long-term lease commitments. All leases are terminable with 2 – 3 months’ notice.

Rent expense was $64,718 and $60,413 for the years ended December 31, 2015 and 2014, respectively.

Employment agreements

As of December 31, 2015 neither the Company nor WL had any direct employees.

Bio-AMD has engaged three employed persons under service agreements identical in nature, and containing terms and conditions which are in the normal course of business.

Effective August 29, 2012 WL entered into a consultancy agreement (the “Consulting Agreement”) with Grabling Services Limited through which the services of Mike Blakey (the “Consultant”) are provided. Mr. Blakey manages the WL business on a day to day basis. Under the Consulting Agreement Mr. Blakey is paid £500 per calendar month (approximately US $760).

F-11

Table of Contents

Consulting agreements

The Company has entered into consulting agreements with outside contractors, certain of whom are also the Company’s stockholders and directors. The Agreements are generally for a term of one year or less from inception and renewable unless either the Company or Consultant terminates such agreement by written notice. The Company incurred $435,202 and $650,533 in consulting fees to these individuals for the years ended December 31, 2015 and 2014, respectively.

Master agreement

On December 17, 2014, we entered into a Master Agreement (the “Agreement”) with Sysmex Corporation (“Sysmex”) pursuant to which the parties will jointly conduct a feasibility study (the “Study”) for the potential development of our POC COAG system including a reader device with disposable test strips for PT-INR assays and potentially new future assays in the field of hemostasis (the “Products’). The results of the Study will form the basis on which we will negotiate with Sysmex the terms and conditions of possible future terms for further development of the Products (the “Research”). Under the terms of the Agreement, Sysmex will own all intellectual property developed by either party in connection with the Study, and will reimburse Bio-AMD Ltd. for costs and expenses incurred in connection with the project development. An expense advance of £642,067 (approximately $950,000) was made to Bio-AMD Ltd. on January 20, 2015. If Sysmex determines the feasibility study to be successful, further cost reimbursements will be made during the term of the Agreement linked directly to milestone criteria and deliverables to be agreed by both parties.

Subsequent to December 31, 2015, the Study has been successfully completed and the results presented to Sysmex which is now clarifying the plan for the next phase of development. There can be no assurance that Sysmex will enter into additional agreements to jointly develop with us the Products or that such a manufacturing/license agreement will ever be consummated or that the Products will ever be commercially sold by Sysmex.

Deferred revenue consists of funds received in advance of services being performed of $950,402 as of December 31, 2015. Revenue will be recognized when the services have been completed and no significant Company obligations remain.

The costs directly associated with the performance of services for which revenue has been deferred are initially capitalized as deferred costs. These costs will be recognized as a component of cost of revenue when the associated revenue is recognized. As of December 31, 2015, these deferred costs amounted to $645,534.

Litigation

Note 6 - Stockholders’ Equity

Common stock:

The Company is authorized to issue 500,000,000 shares of its common stock, with par value of $0.001 per share. As of December 31, 2015 and 2014 there were 45,975,966 and 44,525,966 shares of common stock issued and outstanding, respectively.

During February 2015 we issued 300,000 shares of common stock, valued at $54,000, pursuant to a consulting agreement with a one year term. We have recorded expense of $54,000 in 2015.

During June 2015 we issued 1,150,000 shares of common stock, valued at $184,000, pursuant to a consulting agreement with a six month term.

F-12

Table of Contents

Preferred stock:

The Company is authorized to issue 10,000,000 shares of its preferred stock, with par value of $0.001 per share. As of December 31, 2015 and 2014 there were no shares of preferred stock issued and outstanding.

Note 7 - Warrants

Transactions involving our stock warrants are summarized as follows:

	2015				2014
			Weighted				Weighted
			Average				Average
	Number		Exercise Price		Number		Exercise Price

Outstanding at beginning of the period		5,200,000	$	0.07		5,200,000	$	0.07
Granted during the period		—		—		—		—
Exercised during the period		—		—		—		—
Terminated during the period		—		—		---		---
Outstanding at end of the period		5,200,000	$	0.07		5,200,000	$	0.07
Exercisable at end of the period		5,200,000	$	0.07		5,200,000	$	0.07

The weighted average remaining life of the warrants is 0.8 years at December 31, 2015.

Note 8 - Income Taxes

The Company utilizes ASC 740 “Income Taxes”, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the consolidated financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between consolidated financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

For the years ended December 31, 2015 and 2014, the Company had available for U.S federal income tax purposes net operating loss carryovers of approximately $7,710,000 and $6,926,000, respectively, which expire beginning in 2026. The net operating loss carryovers may be subject to limitations under Internal Revenue Code due to significant changes in the Company’s ownership. The Company has provided a full valuation allowance against the full amount of the net operating loss benefit, since, in the opinion of management, based upon the earnings history of the Company it is more likely than not that the benefits will not be realized.

For the years ended December 31, 2015 and 2014, the Company had available for UK income tax purposes net operating loss carryovers of approximately $3,753,000 and $3,707,000, respectively, which can be carried forward indefinitely. The Company has provided a full valuation allowance against the amount of UK unused net operating loss benefit, since management believes that, based upon the earnings history of the Company, it is more likely than not that the benefits will not be realized.

The income tax provision (benefit) for the years ended December 31, 2015 and 2014 consists of the following:

	December 31,
	2015			2014
Federal:
Current	$	-		$	-
Deferred		288,000			361,000
		288,000			361,000

State and local:
Current		-			-
Deferred		-			-
		-			-

Change in valuation allowance		(288,000	)		(361,000	)

Income tax provision (benefit)	$	-		$	-

F-13

Table of Contents

The provision for income taxes differ from the amount of income tax determined by applying the applicable U.S statutory rate to losses before income tax expense for the years ended December 31, 2015 and 2014 as follows:

	December 31,
	2015			2014
Statutory federal income tax rate		35.0	%		35.0	%
Statutory state and local income tax rate (0%), net of federal benefit		(0.0)	%		(0.0)	%
Foreign tax rate differentials		(0.4)	%		(3.1)	%
Nondeductible items		(0.0)	%		(0.0)	%
Change in valuation allowance		(34.6)	%		(31.9)	%
Effective tax rate		0.0	%		0.0	%

Deferred income taxes result from temporary differences in the recognition of income and expenses for financial reporting purposes and for tax purposes. The tax effect of these temporary differences representing deferred tax asset and liabilities result principally from the following:

	As of December 31,
	2015			2014
Deferred tax assets (liabilities):
Management fees	$	(10,000	)	$	(10,000	)
Stock based compensation		129,000			129,000
US and UK net operating loss carry forward		3,750,000			3,462,000
Less: valuation allowance		(3,869,000	)		(3,581,000	)
Net deferred tax asset	$	-		$	-

The Company has filed its tax returns through December 31, 2014.

The provisions of ASC 740 require companies to recognize in their financial statements the impact of a tax position if that position is more likely than not to be sustained upon audit, based upon the technical merits of the position. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken on a tax return. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and disclosure.

Management does not believe that the Company has any material uncertain tax positions requiring recognition or measurement in accordance with the provisions of ASC 740. Accordingly, the adoption of these provisions of ASC 740 did not have a material effect on the Company’s financial statements. The Company’s policy is to record interest and penalties on uncertain tax positions, if any, as income tax expense.

All tax years for the Company remain subject to future examinations by the applicable taxing authorities.

Note 9 - Segment Information

We currently operate in two segments, 1) the development of a technology designed to mitigate currency risk through our 99.81% owned subsidiary, WL, and 2) the development of highly accurate, low cost, hand held, electronic medical diagnostic devices capable of reading third party assays through our 63% owned subsidiary, Bio-AMD Holdings. Segment information for the years ended December 31, 2015 and 2014 consists of the following:

F-14

Table of Contents

Year ended December 31, 2015:

							Other
	WL			Bio-AMD			(Corporate)			Consolidated

Revenue	$	-		$	-		$	-		$	-
Interest income		15			-			927			942
Other income		1,834			77,674			-			79,508
Segment loss		(36,939	)		(9,399	)		(784,635	)		(830,973	)
Segment assets		3,080			965,628			305,454			1,274,162
Expenditures for segment assets		-			-			-			-

Year ended December 31, 2014:

							Other
	WL			Bio-AMD			(Corporate)			Consolidated

Revenue	$	-		$	-		$	-		$	-
Interest income		14			-			3,387			3,401
Other income		1977			59,154			-			61,131
Segment profit (loss)		(123,497	)		(370,782	)		(636,851	)		(1,131,130	)
Segment assets		17,257			238,642			627,812			883,711
Expenditures for segment assets		-			-			-			-

Note 10 - Subsequent Events

Management evaluated all activities of the Company through the issuance date of the Company’s consolidated financial statements and concluded that no subsequent events have occurred that would require adjustments or disclosure into the consolidated financial statements.

F-15

Attached files

Bio-AMD Inc. Reports

Also read